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Δε:   Extinction coefficient 
A:   Ampere 
Amp:   Ampicillin 
AU:   Absorbance Unit 
BME:   β–mercaptoethanol 
bp:   base pair 
BSA:   Bovine Serum Albumin 
Cam:   Chloramphenicol 
CV:   Column Volume 
Da:   Dalton 
ddH2O:  Double-distilled water 
dNTP:   Deoxyribonucleotide 
E. coli:   Escherichia coli 
EDTA:  Ethylene Diamine-Tetra-acetic Acid 
Etest:   Epsilometer test 
Hepes:   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG:   Isopropyl-β-D-1-thiogalactopyranoside 
kcat:   Turnover number in Michaelis-Menten kinetics 
Km: Dissociation constant for enzyme-substrate (ES) complex in Michael-
Menten equation 
LB:   Lysogeny Broth 
LDS:   Lithium dodecyl sulphate 
MBL:    Metallo-β-lactamase  
MIC:   Minimum inhibitory concentration 
min:   Minutes 
mRNA:  messenger RNA 
OD:   Optical density 
o/n:   overnight 
P. aeruginosa: Pseudomonas aeruginosa 
Pa:   Pascal 
PBP:    Penicillin-binding protein 
PCR:    Polymerase chain reaction 
PEG:   Polyethylene glycol 
2
  
PEG MME:  Polyethylene glycol monomethyl ether 
rpm:   Rounds per minute 
SB:   Sample buffer 
SBL:   Serine-β-lactamase 
SDS-PAGE:   Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SOB:    Super Optimal Broth 
TAE:    Tris-acetate-EDTA  
TEV:   Tobacco Etch Virus 
TGX:   Tris-Glycine-Extended 
VIM:   Verona integron-encoded metallo-β-lactamase 





















 The metallo-β-lactamases (MBLs) are enzymes with the ability to hydrolyse the β-
lactam antibiotics. The worldwide emergence of the antibiotic resistant MBLs poses an 
increasing clinical threat. The VIM enzymes are a growing family of carbapenemases with a 
wide geographic distribution in Europe, South America and the USA. The VIM-7, the first 
VIM enzyme to be discovered in the USA, is the most divergent member of the VIM-
enzymes with the closest similarity to VIM-1 with a 77% amino acid identity. The VIM-7 has 
a conserved D120 in the active site, which, in catalysis, plays an important role. The Y224 
residue present in the VIM-2, which currently is the most widespread MBL, is though to have 
an impact on the activity. Three site-directed mutations of the VIM-7, with a previously 
solved structure, were made; D120A, D120N and H224Y respectively. All three mutants and 
the VIM-7 wt were sequenced, and the mutants VIM-7 D120A and VIM-7 H224Y with the 
VIM-7 wt, containing an N-terminal hexahis-tag and cleavage site, were produced, affinity 
purified and tested in a nitrocefin activity assay. The nitrocefin activity assay showed that the 
VIM-7 D120A mutant was inactive. In addition, the VIM-7 H224Y mutant was purified using 
gel filtration. A crystal was obtained of the VIM-7 H224Y mutant, and the crystal structure 
was solved. Enzyme kinetic studies were performed on the VIM-7 wt and the VM-7 H224Y, 
which resulted in the VIM-7 H224Y to have a significantly higher catalytic efficiency 
towards specific antibiotic substrates than the VIM-7 wt. The VIM-7 D120A mutant would 
not hydrolyse the antibiotic substrate ertapenem, and was not tested with other antibiotics. 
The inactive VIM-7 D120A and the active VIM-7 H224Y showed that by mutating one single 
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Aim of study 
 The aim of this project was to produce three different site-directed mutations, each 
close to the active site to investigate how the mutants would affect the specificity of VIM-7 
against a series of antibiotics. The mutants were expected to have different effects on the 
activity compared to the wild type. The mutants were expressed and purified before a 
biochemical characterization was performed. An optimistically aim was to perform 
























 Antibiotic resistance has been known for 65 years, but the number of antibiotic 
resistant organisms and their breadth of resistance is increasing [1]. The metallo-β-lactamases 
(MBLs), present in many clinically important human bacterial pathogens, represent a growing 
challenge to the effectiveness of β-lactams, which are still the most widely prescribed class of 
antibiotics [2]. The MBLs encoded on transferable genes are easily spread, which makes 
surveillance studies and MBL inhibitor studies important [3]. In this study, mutations on the 
MBL VIM-7 will be performed to understand the selected residues’ importance, in the active 
site, for enzyme activity.  
 
β-lactams vs. metallo-β-lactamases – in the fight against resistance 
For the last 60 years, β-lactams have been the most widely used antibiotics. β-lactams 
includes the following classes; penicillins, cephalosporins, monobactams and carbapenems, 
and they inhibit a transpeptidase involved in the cell wall biosynthesis [4]. A common feature 
of the molecular structure of the β-lactam antibiotics is a four-atom ring known as a β-lactam 
(Figure 1). The β-lactams are the largest group of antibiotics prescribed in Norway with a 
total human usage of 45% of all antibiotics used [5].  
Some bacteria develop a resistance to β-lactam antibiotics by producing enzymes 
called β-lactamases, which hydrolyses the amide bond of the β-lactam ring. This makes the β-
lactamases very important clinically. The β-lactamases are classified into four classes A-D [6, 
7]. These are again divided into two superfamilies; the serine β-lactamases (SBLs), which 
entail class A, C and D, and metallo-β-lactamases (MBLs), which is class B of the Amber 
classification of β-lactamases [8]. According to the Bush-Jacoby classification of β-
lactamases, the MBL belong to group 3 [9]. SBLs are characterized, as the name implies, by a 
serine moiety in the active site [10], while the MBLs are characterized by one or two metal 
ions, usually zinc, that functions as cofactors for enzyme activity [11]. The MBLs are further 
divided into subgroups B1, B2 and B3 according to their structural features and sequence 
identity, where most MBLs belong to group B1 [12]. All β-lactam antibiotics are hydrolysed 
by MBLs, with the monobactam aztreonam as an exception. Clinically, the MBLs are 
important because they are not inactivated by useful inhibitors, while many of the SBLs are 
inactivated [13, 14]. The MBLs are often expressed in combination with other β-lactamases in 





Figure 1: The cleavage of the β-lactam ring by the β-lactamases. a) The β-lactam ring. b) The action of β-
lactamases on the β-lactam antibiotics. The C1-N bond of the β-lactam ring is broken by the β-lactamase, and the 
β-lactam antibiotics’ properties are deactivated. Figures obtained from Wikipedia. 
  
 In the 1960s, the first discovery of MBL was made, in a strain of Bacillus cereus [15, 
16]. The MBLs are known to be expressed by at least twenty different strains, this including 
Pseudonomas aeruginosa [17, 18], Klebsiella pneumoniae [19], Serratia marcescens [20], 
Aeromonas hydrophila [21], Aeromonas veronii [22], Stenotrophomonas maltophilia [23], 
and Bacteroids fragilis [24, 25], where some of the strains are human pathogens.  
As mentioned earlier, the MBLs need one (subclass B2) or two (subclass B1 and B3) 
active-site zinc ions for β-lactam hydrolysis. The location of the zinc atoms, in the B1 
subclass, is at the opening in the wide groove between two β-sheets (Figure 2). The zinc ions 
are bridged with a water/hydroxide ion, and differences in the dizinc center and the substrate 
binding sites contribute in determining the MBLs catalytic efficiency towards the bound 
substrate. Although the MBLs have a low level of overall amino acid similarity, they share 
the αββα sandwich structure consisting of two β-sheets at the core and five external α-helices 
(Figure 2) [26]. The MBL proteins include the enzymes thiolesterases, which are members of 
the glyoxalase II family. The thiolesterases catalyse the hydrolysis of S-D-lactoyl-glutathione 





Figure 2: The structure of VIM-7 which belongs to the MBL molecular class B1. The Zn ions are in 
indicated by orange spheres, and the bridging water molecule in red. The figure is made in PyMOL using the 
VIM-7 structure obtained from RCSB PDB ID: 2Y87 [29]. 
 
Pseudomonas aeruginosa 
The MBL VIM-7 was found in P. aeruginosa, which is a common bacterium that can 
cause disease in humans and animals [30]. P. aeruginosa is found in most man-made 
environments in the world in addition to soil, water and skin flora. Not only does it thrive in 
normal atmosphere, but also in hypoxic atmosphere, meaning atmosphere where the dissolved 
oxygen in water is below the level necessary to sustain most animal life. Because the bacteria 
can survive on most surfaces, it is also found in and on medical equipment, such as catheters, 
which causes cross-infections in hospitals. On the other hand, the bacteria are able to 
decompose hydrocarbons and have been contributory in breaking down tarballs and oil from 
oil spills [31]. One of the most opportunistic bacterial pathogens in patients with chronic 





Verona integron-encoded metallo-β-lactamase 7 (VIM-7) 
 The Verona integron-encoded metallo-β-lactamase (VIM) was first reported in Italy in 
1996 [33], hence, numbered 1, and the VIM is a growing family of carbapenemases, which 
now have a wide geographic distribution in Europe [34-37], South America [38], and have 
also been found in the United States [39]. VIM-1 was discovered in 1996 in P. aeruginosa (P. 
aeruginosa) at the University of Verona in Italy, and is the origin to the name VIM. In most 
countries in Europe the VIM-2 has been isolated from several strains, and is today the 
dominant type of VIM [40]. The VIM MBLs belong to the B1 subgroup, which has two 
flexible loops thought to interact with bound substrate and inhibition molecules [26]. The 
VIM enzymes are mostly occurring in P. aeruginosa, Pseudonomas putida (P. putida) [35], 
and occasionally in Enterobacteriaceae [41]. Due to the world-wide distribution, the VIM-
enzymes are the most clinically important MLBs. VIM-7 was the first MBL reported from the 
United States. In a clinical isolate of P. aeruginosa from Texas, the VIM-7 was identified on 
a 24 kb plasmid [42]. The VIM-7, compared to other VIM-type MBLs, differ the most in 
terms of the amino acid sequence. VIM-7 is closest related to VIM-1 and VIM-4 with a 77% 
sequence identity and a 74% sequence identity to VIM-2 [3]. The VIM-7 amino acid and 
nucleotide sequence is shown in figure 3 below. The secondary structure elements and 
sequence alignment of VIM-7 and VIM-2 are shown in figure 4 below, including β-sheets and 
α-helices.  
 Enzyme kinetic studies of VIM-7 have shown that it efficiently hydrolyzes the β-
lactams penicillins and carbapenem, except for ertapenem. For the β-lactams cephalosporins, 
















     1   M  F  Q  I  R  S  F  L  V  G  I  S  A  F  V  M  A  V  L  G  
     1  ATGTTTCAAATTCGCAGCTTTCTGGTTGGTATCAGTGCATTCGTCATGGCCGTACTTGGA 
 
    21   S  A  A  Y  S  A  Q  P  G  G  E  Y  P  T  V  D  D  I  P  V  
    61  TCAGCAGCATATTCCGCACAGCCTGGCGGTGAATATCCGACAGTAGATGACATACCGGTA 
 
    41   G  E  V  R  L  Y  K  I  G  D  G  V  W  S  H  I  A  T  Q  K  
   121  GGGGAAGTTCGGCTGTACAAGATTGGCGATGGCGTTTGGTCGCATATCGCAACTCAGAAA 
 
    61   L  G  D  T  V  Y  S  S  N  G  L  I  V  R  D  A  D  E  L  L  
   181  CTCGGTGACACGGTGTACTCGTCTAATGGACTTATCGTCCGCGATGCTGATGAGTTGCTT 
 
    81   L  I  D  T  A  W  G  A  K  N  T  V  A  L  L  A  E  I  E  K  
   241  CTTATTGATACAGCGTGGGGGGCGAAGAACACGGTAGCCCTTCTCGCGGAGATTGAAAAG 
 
   101   Q  I  G  L  P  V  T  R  S  I  S  T  H  F  H  D  D  R  V  G  
   301  CAAATTGGACTTCCAGTAACGCGCTCAATTTCTACGCACTTCCATGACGATCGAGTCGGT 
 
   121   G  V  D  V  L  R  A  A  G  V  A  T  Y  T  S  P  L  T  R  Q  
   361  GGAGTTGATGTCCTCCGGGCGGCTGGAGTGGCAACGTACACCTCACCCTTGACACGCCAG 
 
   141   L  A  E  A  A  G  N  E  V  P  A  H  S  L  K  A  L  S  S  S  
   421  CTGGCCGAAGCGGCGGGAAACGAGGTGCCTGCGCACTCTCTAAAAGCGCTCTCCTCTAGT 
 
   161   G  D  V  V  R  F  G  P  V  E  V  F  Y  P  G  A  A  H  S  G  
   481  GGAGATGTGGTGCGCTTCGGTCCCGTAGAGGTTTTCTATCCTGGTGCTGCGCATTCGGGC 
 
   181   D  N  L  V  V  Y  V  P  A  V  R  V  L  F  G  G  C  A  V  H  
   541  GACAATCTTGTGGTATACGTGCCGGCCGTGCGCGTACTGTTTGGTGGCTGTGCAGTTCAT 
 
   201   E  A  S  R  E  S  A  G  N  V  A  D  A  N  L  A  E  W  P  A  
   601  GAGGCGTCACGCGAATCCGCGGGTAATGTTGCCGATGCCAATTTGGCAGAATGGCCTGCT 
 
   221   T  I  K  R  I  Q  Q  R  Y  P  E  A  E  V  V  I  P  G  H  G  
   661  ACCATTAAACGAATTCAACAGCGGTATCCGGAAGCAGAGGTCGTCATCCCCGGCCACGGT 
 
   241   L  P  G  G  L  E  L  L  Q  H  T  T  N  V  V  K  T  H  K  V  
   721  CTACCGGGCGGTCTGGAATTGCTCCAACACACAACTAACGTTGTCAAAACGCACAAAGTA 
 
   261   R  P  V  A  E  -  
   781  CGCCCGGTGGCCGAGTAA 
 
Figure 3: The protein coding sequence of the VIM-7 gene. The amino acid sequence is shown above and 
nucleotide sequence below. Numbering of sequences is given to the left. In this thesis a construct for A26-E265 
was cloned. A26 is indicated in bold. The selected sites for mutations, here indicated as D117 and H200, while 
according to the BBL standard numbering scheme [12] is D120 and H224 are indicated in bold. Figure obtained 




Figure 4: Sequence alignment and secondary structure elements of VIM-7 and VIM-2. The residues of 
VIM-7 and VIM-2 are numbered according to the standard numbering scheme for class B beta-lactamases [44]. 
The residues binding the zinc are indicated with triangles (▲). PDB ID: 2YZ3 [29]. 
 
Selected site-directed mutations of VIM-7 
 In this thesis, a D120A mutant, D120N mutant and a H224Y mutant of VIM-7 were 
made. Previous studies of D120 residue mutations in other MBLs have shown to have an 
impact on the activity of the enzyme. The 224 position was proposed to play a role in the 
activity, as the VIM-2 had a tyrosine amino acid at the 224 residue, and VIM-7 had a histidine 
amino acid.  
Studies have shown that the D120 residue in the active site is important for MBLs to 
binding of Zn and therefore for proper binding of substrate to the enzyme [4, 45]. The aspartic 
acid (D) residues can have three major functions in enzymes: 1) contribute in coordination of 
the Zn ions to ensure the optimal position for catalytic activity, and therefore 2) hydrogen 
bonding with active site residues and substrates, and 3) shuttling protons from and to groups 
in the active site [4]. The coordination of Zn ions is done by D120, with unbound oxygen 
located directly above the bridging group in the active site (Figure 5). The interactions of the 
D120 residue with water molecules in the active site are important to transfer protons and a 
possible nucleophilic attack by the metal-bridging water/hydroxide on the β-lactam carbonyl 
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carbon of the amide bond. Hence, the D120 residue plays an important role in the enzymatic 
activity of the MBL [4]. It has also been hypothesized that D120, in addition to being a metal-
binding ligand, electrostatically interacts with the bridging hydroxide, properly positioning it 
for nucleophilic attack on the substrate. The incoming water molecule acts as a proton donor 
to the nitrogen leaving group of the substrate [45]. One proposed reaction mechanism is 
shown in figure 6. The carboxylate side chain of D120 binds directly with the metal-bridging 
water/hydroxide, via hydrogen bonding, and with the Zn ion. 
Samuelsen et al [43], showed that the catalytic efficiency for cephalosporins was 
generally higher for VIM-1 and VIM-2, compared to the catalytic efficiency of VIM-7. The 
cephalosporin moxalactam was the only exception of the nine cephalosporin substrates tested. 
The catalytic efficiency of the carbapenems was similar between VIM-7 and VIM-2, while 
the efficiency of the penicillins was higher for VIM-7, compared to the VIM-1 and VIM-2. 
By studying the active site of VIM-1, VIM-2 and VIM-7 (Figure 5), there are some 
differences. Most VIMs have histidine at the 224 position, while VIM-2 has a tyrosine. It was 
suggested that the Tyrosine-224 of the VIM-2 interacts with the charged R2 substituents of 
some β-lactams (present in some cephalosporin substrates), and that the tyrosine hydroxyl 
group makes a second-shell metal-ligand interaction by hydrogen bonding via a water 









Figure 5: The active sites of VIM-2. Active site residues for VIM-2 are shown in green. Light cyan coloured 
residues represent the aligned residues in VIM-1 and VIM-7. The atom colours are; carbon is shown in green, 
oxygen in red, nitrogen in blue and sulphur in yellow. The two zinc ions (Zn1 and Zn2) are marked as grey, and 
the two water molecules (Wat-1 and Wat-X) as red spheres. The numbering of the residues is according to the 
BBL standard numbering scheme [12]. Thin gray lines show the metal-ligands and hydrogen bonds. The VIM-1 
and VIM-7 models’ side chains are of Ser68, Phe218 and His224 are shown in cyan. Figure adapted from 
Samuelsen et al [43]. 
 
 
Figure 6: The proposed reaction mechanism showing the role of the D120 residue in the active site of the 
VIM-7. The D120 orients the metal-bound water/hydroxide (OH-) for it to make the initial nucleophilic attack on 
the bound cephalosporin substrate. Another water molecule protonates the amide nitrogen and replaces the first 





Classification of antibiotics 
More than 12 000 antibiotics with a variety of modes of action and with different 
specificities have been extracted from different microorganisms, since the late 1920s when 
penicillin was first discovered [46, 47]. The first use of the term “antibiotic” in the present 
sense was by the American microbiologist Waksman and his colleagues in 1941 [48]. 
Waksman [49] defined antibiotic as following; “an antibiotic is a chemical substance, 
produced by micro-organisms, which has the capacity to inhibit the growth of and even to 
destroy bacteria and other micro-organisms.” A common classification system is based on the 
biological activity of the antibiotics [50]; group 1, bacteriostatic antibiotics, where the growth 
of the bacteria is inhibited (the bacteria is kept in the stationary growth), and group 2, 
bactericidal antibiotics, where the bacteria is killed. The biological activity can be estimated 
for group 1 by measuring the minimal inhibitory concentration (MIC). MIC is the lowest 
concentration of antibiotics needed to inhibit the growth of a microorganism. For group 2, the 
minimal bactericidal concentration (MBC) is measured, which is the lowest concentration of 
antibiotics that kills the bacteria.  
Several other classification systems have been developed based on; chemical origin 
(natural, semisynthetic, or synthetic), or their mechanism of action is shown in figure 7, a 
spectrum of activity, or chemical structure. The specificity of the activity is classifies as; 
broad-spectrum, where the antibiotics affect a wide variety of bacteria, and narrow-spectrum, 
where antibiotics affect specific types of bacteria, like Gram-negative or Gram-positive 
bacteria. It has been proposed and partly proved that the development of antibiotic resistance 





Figure 7: Antibiotics mechanism of action on the bacteria cell.  The different classes of antibiotics are shown 
here in β-lactams affects the cell wall synthesis. Figure obtained from Wikipedia. 
 
Every year, over 100 000 tons of antibiotics are produced, worldwide, with annual 
sales of about $35 billion, this including antibiotics used as animal growth promoters and in 
animal feed. In the antibiotic market, the sales are driven by four leading drug classes: the 
cephalosporins (27%), macrolides (20%), quinolones (17%), and penicillins (17%). These 
four drug classes, together, account for more than 80% of the global antibacterial sales [46].  
 
Macrolides 
 Macrolide is a term used to describe drugs containing a macrocyclic lactone ring of 12 
or more elements (figure 8). The macrolides with 14-, 15-, and 16-membered rings are a 
widely used family of antibiotics [52]. By binding to the large ribosomal subunit in the 
peptidyl transferase center, the macrolides cause cell growth to stop due to inhibition of 
protein synthesis [53, 54]. Clinical applications of macrolides are; in the treatment of upper 
respiratory tract infections [55] and as immunomodulatory medication, as they have the 




Figure 8: The chemical structure of Clarithromycin. The macrolide ring is the cyclic ester (lactone) to the left. 
Figure obtained from Wikipedia. 
 
Quinolones 
 The quinolones are a group of broad-spectrum antibiotics [57, 58], which are produced 
synthetically. The chemical structure of the quinolone backbone is shown in figure 9. In the 
clinical use of quinolones, the majority has a fluoride substitute on the central ring system, 
and belongs to the subgroup called flouroquinolones [59]. The mechanism of action of 
quinolones is to prevent bacterial DNA from unwinding and duplicate, this is done by 
inhibiting the bacterial DNA gyrase (gram-negative bacteria) or the topoisomerase IV enzyme 
(gram-positive bacteria) [60, 61]. The result of the inhibition is bacterial cell death.  
 
Figure 9: The chemical structure of the quinolone backbone. The blue R (to the right) is usually piperazine 









The β-lactams antibiotics are a broad group of antibiotics, where all antibiotic agents 
have a β-lactam ring in their structure (Figure 1a), which includes the antibiotics; 
carbapenems, cephalosporins, penicillin, and monobactams [62]. The β-lactam antibiotics 
function by inhibiting the synthesis of the peptidoglycan layer of the cell walls of Gram-
positive and -negative bacteria. Especially in Gram-positive bacteria this peptidoglycan layer 
is important for cell wall structure. Transpeptidases known as penicillin-binding proteins 
(PBPs) facilitate the final transpeptidation step in the synthesis of peptidoglycan. A β-lactam 
ring is found in the structure of all β-lactam antibiotics. The β-lactam antibiotics’ ability to 
reach the PBP intact and their ability to bind to the PBP, decides how efficient they are as 
antibiotics. The various functional groups have been chemically added to the cyclic amide 
ring in the β-lactam series, which have formed a family of active compound with different 
specificities [63, 64]. 
The inhibition of the cell wall biosynthesis triggers the release of bacterial autolysin, leading 
to cell lysis and death [65]. Measured by sales up until 2003, the β-lactams compounds was to 
be found in more than half of all commercially available antibiotics [66]. In the following, a 
selection of relevant β-lactams will be presented. 
 
Penicillin 
 The chemical structure of a penicillin backbone [67] is shown in figure 10 below. The 
core skeleton of a penicillin antibiotic is named penem. The side chain R varies [68].  
Penicillin is the oldest known β-lactam antibiotic, and it was discovered by a 
coincidence. Sir Alexander Fleming was trying to multiply the penicillium fungi in the lab in 
1928 [69]. Ernst Boris Chain and Sir Howard Walter Florey, at Oxford, contributing in 
bringing penicillin’s potential for medical use to maturation and, together with Fleming, 
received the Nobel Prize in Physiology or Medicine in 1945 [70].  
Examples of penicillins; benzylpenicillin (also known as penicillin G), ampicillin [71], 





Figure 10: The chemical structure of the penicillin backbone. The R group of the penicillin is variable. The 
β-lactam ring is located to the left, and a thiazolidine ring to the right. Figure obtained from Wikipedia. 
 
Monobactam 
 In contrast to other β-lactams, the monobactams have a β-lactam ring which is not 
fused to another ring (figure 11). The only marketed monobactam is aztreonam. The 
synthetically produced aztreonam is specific towards aerobic gram-negative bacteria [73, 74]. 
Aztreonam has not been used a lot clinically, because the third-generation cephalosporins 
available have a broader spectrum of activity [75]. 
 
Figure 11: The chemical structure of the monobactam, Aztreonam. The β-lactam ring is to the right below. 







 The carbapenem class of β-lactams have a broad spectrum of antibiotic activity, with a 
structure that contributes to a strong resistance towards most β-lactamases (Figure 12) [76]. 
Originally, the carbapenems were developed from thienamycin, as a natural product of 
Streptomyces cattleya. The thienamycin, however, was chemically instable, and was followed  
by the N-formimidoyl derivate, imipenem [77]. Other examples of carbapenems are 
meropenem [78] and ertapenem [79]. 
 
Figure 12: The chemical structure of the carbapenem backbone. The β-lactam ring is located to the left, and 
the R groups are variable. Figure obtained from Wikipedia. 
 
Cephalosporins 
 The cephalosporins, together with cephamycins, are a subgroup of β-lactam antibiotics 
cephems [80]. Originally, the cephalosporins were derived from the fungus Acremonium, 
which was previously known as cephalosporium [81]. Cephalosporins and cephamycins are 
very similar, the difference is a methoxyl group in the 1 position of the cephamycin and an 
acetoxy group at 2 position of the cephalosporin, while cephamycins have other substituents 
after the acetoxy group [82] (position 1 and 2 indicated in figure 13). The similarity between 
the cephalosporins and the cephamycins is the reason for the cephamycines sometimes being 
termed as cephalosporins. Originally, the cephamycins was produced by Streptomyces [83], 
but synthetic antibiotics have also been produced. Cefoxitin is an example of a cephamycin 
[84]. The cephalosporins are normally classified into “generations” according to their 
antimicrobial properties [75]. The first-generation cephalosporins were the first 
cephalosporins entitled, while later, cephalosporins with more extended-spectrum were 
named second-generation cephalosporins. Each new generation of cephalosporins has a 
spectrum more concentrated towards Gram-negative bacteria. Examples of cephalosporins; 
cefacetrile [85] (first-generation), cefuroxime [86] and cefoxitin (second-generation), 
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Figure 13: The chemical structure of the backbone of cephalosporin. The β-lactam ring is located to the left. 
The numbers 1 and two at the carbons indicate where the difference between cephalosporins and cephamycins is. 
R1 and R 2 are variable groups. Figure obtained from Wikipedia. 
 
Nitrocefin 
 Nitrocefin is not an antibiotic, but a chemical compound widely used to detect the 
activity of β-lactamases [90-93] and used in kinetic analysis [94-96]. Nitrocefin is 
characterized as a chromogenic cephalosporin. Cephalosporins has an absorbance at around 
260 nm [97], while the nitrocefin has an absorbance of 482 nm [98]. A reason for nitrocefin 
having an absorbance is due to highly conjugation with the R2 group[98]. The amide bond in 
the β-lactam ring of nitrocefin is hydrolysed by β-lactamases, resulting in a color change from 
yellow to red (figure 14).  
 
 
Figure 14: The chemical structure of nitrocefin. The β-lactam ring is the second ring from the left, connected 




Since the early 1940s, drug resistance has been known, and although many 
international reports, including the report of the World Health Organization [99], the problem 
grows and evolves from decade to decade.  
The global public health is threatened by the current increase in antibiotic resistance, 
which involves all major microbial pathogens and antimicrobial drugs [1]. There are several 
reasons for the global concern when it comes to antibiotic resistance; i) it kills, ii) increases 
the cost of health care, iii) prevents control of infectious diseases, and iv) endangers the health 
care gains to society.  
Antibiotic resistance appears when a microorganism survives being exposed to an 
antibiotic. Antibiotic resistance is a type of drug resistance. Resistant organisms, which 
include viruses, bacteria and some parasites, are able to combat attack by antimicrobial 
medicines (like antibiotics, antivirals, and antimaterials) making the standard treatments 
become ineffective. The resistant infections might also spread to other people. Some bacteria 
have been characterized as multiple antibiotic resistant. Severe clinical problems and the cost 
of lives are posed by drug resistant strains, especially in developing countries. The spread is 
often aided by poor sanitation conditions, and new effective but more expensive, antibiotics 
are not reached because of small healthcare budgets [100]. For example, a re-emergence of 
tuberculosis, which often is multidrug resistant, has occurred since the 1980s, and has been 
enhanced by human immunodeficiency virus infections (HIV) [101]. The β-lactamases with 
their broad-spectrum activities do also destroy the latest generations of cephalosporins and 
penicillin [102]. Carbapenem-drugs are often the ‘last resort’ of serious infections of Gram-
negative bacteria, and the carbapenems are inactivated by strains bearing the MBLs [76, 103]. 
The MBLs are thus considered a great threat to humans. 
 Bacteria become antibiotic resistant as the genes encoding the resistance are spread 
from one bacterium to another through plasmids, bacteriophages, naked DNA or transposons. 
Some complex transposons have integrons that are used for integrating different antibiotic 
resistance genes [104]. An integron is a mobile DNA element with the ability to capture and 
carry genes, and the antibiotic resistance genes are located on gene cassettes, which can exist 
as free circular DNA. A recombination event integrates the gene cassette into the integron. 
Chromosomal genes can be transferred by naked DNA. The naked DNA is released from one 
microorganism and can be taken up by another bacterium. This was the mechanism for 
penicillin resistance [105, 106]. Bacteria, being mobile, can easily be transferred from one 
person to another and it can spread between countries [107]. 
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 When patients have an emergence of resistant bacteria as a result of using antibiotics, 
it normally occurs through a process named ‘selective pressure’. Studies have shown that 
small numbers of bacteria, that are basically resistant towards antibiotics, are normally 
harbored in healthy persons [108]. Resistant bacteria are usually held back by large numbers 
of antibiotic-susceptible organisms. The organisms susceptible to the antibiotic at the site of 
infection are eliminated by the use of the antibiotic. The antibiotic is further spread in 
adequate concentrations to all sites in the body. When the numbers of natural flora is 
decreased by the administration of an antibiotic, which allows resistant bacteria to proliferate, 
a selective pressure has happened [109].  
 Several different causes for antibiotic resistance have been proposed; i) unnecessary 
use of antibiotics by humans, ii) availability over-the-counter in many countries, iii) patient 
failure to follow prescribed course of treatment, iv) misuse by health professionals, v) use in 
animal feeds in low doses, vi) antibiotic application in family pets, agriculture, and aquaria, 
and vii) eating raw or undercooked foods [110].  
 There are some actions for limiting the development of antibiotic resistance; only use 
antibiotics for bacterial infections, if possible, identify the causative organism, finish the full 
treatment (not stop antibiotics as soon as symptoms diminish), and use the right antibiotics 





The enzyme kinetics is used to study the catalytic efficiency of different antibiotics on 
MBLs. Living systems depend on chemical reactions which, on their own, would occur at 
extremely slow rates. Enzymes are catalysts which reduce the needed activation energy so 
these reactions proceed at rates that are useful to the cell. 
In this thesis, the Michaelis-Menten equation is used to study the enzyme kinetics of 
VIM-7, and its mutants’ hydrolysis of β-lactam substrates. The Michaelis-Menten model is 
given below (equation 1), by relating reaction rate (V0) to the concentration of a substrate [S], 
which describes the rate of enzymatic reactions [111, 112]. 
 
The Vmax and Km are kinetic constants, where Vmax represents the maximum rate 
achieved by the system, while Km represents the substrate concentration at which the reaction 
rate is half of Vmax (Figure 15). Km indicates how efficiently an enzyme selects its substrate 
and converts it to product.  
The German biochemist Leonor Michaelis and the Canadian physician Maud Menten 
proposed a mathematical model of the reaction involving an enzyme, E, binding to a substrate, 
S, to form a complex of enzyme and substrate, ES, which is then converted into a product, P, 
and the enzyme, (equation 2). 
 
The kf, kr and kcat are the rate constants that describe the rate of the ES complex 
formation, and formation of product and the reverse formation of substrate from the complex. 
The double arrows between S and ES show that the enzyme-substrate binding is a reversible 
process. In order to convert this equation into analysis of Vmax and Km, we have to assume 
that the concentration of ES is steady during the kinetic reaction and the formation of ES from 
E + P is negligible, since the concentrations of product is rather low at the start of the reaction. 
The kcat is known as the turnover number, and tells the maximum number of substrate 
molecules converted to product per enzyme molecule per second. Km tells the binding affinity 
of the substrate to the enzyme. When dividing kcat/Km, you get an estimate of the enzymes 
efficiency catalysis [113].  
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In enzyme kinetics the reaction rate, V0, can not further increase at very high substrate 
concentration, which means it will reach a maximum value of Vmax [114]. The Michaelis-
Menten equation (equation 1) can be illustrated by a curve (Figure 15) with the following 
assumptions made: 
 There is no allostericity or cooperation, and the mechanism does not involve 
intermediate or product inhibition. 
 The total enzyme concentration does not change over time. 
 The concentration of the substrate-bound enzyme [ES], and the unbound 
enzyme [E]0, are changing more slowly than the concentration of the product 




Figure 15: The Michaelis-Menten kinetics curve. The saturation curve shows the relationship between 
substrate concentration and the reaction rate of an enzyme and shows how the kinetic constants Km and Vmax can 
be derived. Vmax represents the maximum rate of the reaction, and Km is defined by the substrate concentration 









Materials and methods 
Table 1: Content of buffers and solutions used for cloning of VIM-7, protein expression and purification 
of the VIM-7 wt and the mutants. 
 Contents 
LB 1% (w/v) bacto tryptone, 0.5% (w/v) bacto yeast extract, 1% (w/v) NaCl, in 
ddH2O  
LB-agar 1% (w/v) bacto tryptone, 0.5% (w/v) bacto yeast extract, 1% (w/v) NaCl, 
1.5% (w/v) agar-agar, in ddH2O 
TB 1.2% (w/v) peptone, 2.4% (w/v) yeast extract, 72 mM K2HPO4, 17 mM 
KH2PO4, 0.4% glycerol 
SOB 2% (w/v) bacto-peptone, 0.5% (w/v) Yeast extract, 10 mM NaCl, 2.5 mM 
KCl, in ddH2O  
Cam 35 mg/ml Chloramphenicol in 100% Ethanol 
Amp 100 mg/ml Ampicillin in ddH2O 
IPTG 0.4 mM Isopropyl-β-D-1-thiogalactopyranoside in ddH2O 
TAE-buffer 40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
Buffer A 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 100 µM ZnCl2 
Buffer B 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 100 µM ZnCl2, 10 mM Imidazole 
Buffer C 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 100 µM ZnCl2, 1 M Imidazole 
Buffer D 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM BME 
Buffer E 50 mM Hepes pH 7.2, 100 µM ZnCl2. 
Buffer F 50 mM Hepes pH 7.2, 100 µM ZnCl2, 1 mg/ml Bovine Serum Albumin 
Buffer G 10 mM Tris-HCl pH 8.0, 1 mM EDTA 
 
Cloning of VIM-7 
The VIM-7 protein, originating from the blaVIM-7 gene (M1-E265 figure 4) from the P. 
aeruginosa strain 07-406 [42], subcloned in a pET26b(+) vector by Samuelsen et al [43], was 
cloned. At the N-terminal of the sequence of blaVIM-7, there is a 25 residue long region which 
gives high scores in the programme SignalP [115, 116].This indicates that the gene has a 
signal sequence which might cause the produced protein to be transported out of the nucleus 
to the periplasm. To avoid secretion of the protein to the periplasm, the primers were designed 
to allow the protein coding sequence to start at Ala26, hence, removing the signal sequence. 
By this strategy the construct would encode amino acids A26-E265 of VIM-7. 
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Three primers were designed based on the nucleotide sequence of the blaVIM-7 gene 
(EMBL Bank Entry: AM778842.1) [42]. The first primer, the VIM-7 Ala26 forward primer, 
encodes a hexahistidine tag (His-tag) at the N-terminal (shown in italic below), that allows for 
affinity purification of the tagged recombinant protein from endogenous proteins in the 
bacterial host E. coli. In addition, a TEV protease specific cleavage site (shown in underline 
below) was cloned following the his-tag, which allows for tag-removal. Finally, this primer 
contained a gene-specific sequence complementary to the blaVIM-7 (shown in bold, italic and 
underlined below).  
The VIM-7 reverse primer encodes a gene specific sequence (shown in bold, italic and 
underlined), in addition to an attB2 site (shown in bold and underlined) followed by a stop 
codon (shown in bold below).  
Following gene-specific amplification with VIM-7 Ala26 fwd and VIM-7 rev, a PCR 
with adapter primer was performed to include the Gateway attB1 (shown in italic and 
underlined below) and attB2 recombination sequences to perform the Gateway cloning. In 
addition, this primer contained a Shine-Dalgerno sequence, seven nucleotides upstream from 
the start codon, (shown normal in red below), that allows the ribosome to bind the mRNA and 
initiate protein synthesis. The start codon ATG (shown in bold below) is placed after the 
Shine-Dalgerno sequence, followed by a His-tag (shown in italic).  
Overview of primers: 
 
 VIM-7 Ala26 fwd 
5’ - CATCACCATCACCATCACGAAAACCTGTATTTCCAGGGAGCA 
GCACAGCCTGGCGGTGAATATCCG - 3’ 
 
 VIM-7 rev (reverse and complementary of DNA)  
5’ - GGGGACCACTTTGTACAAGAAAGCTGGGTCTTA 
CTCGGCCACCGGGCGTACTTTG - 3’ 
 
 Forward Primer 2: attB1-His fwd (adapter primer) 
5 – GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACC 
ATGCATCACCATCACCATCAC - 3’   
 
Polymerase chain reaction (PCR) is a scientific technique for generating large 
quantities of a specific DNA sequence in vitro [46]. The Phusion PCR consisted of 1x HF 
buffer (Thermo Science), 200 µM dNTP mix (Thermo Science), 0.5 µM forward primer 
(VIM-7 Ala26 fwd, described above), 0.5 µM reverse primer (VIM-7 rev, described above), 
approximately 100 ng VIM-7 pET26b(+) template, 0.02 U/µl Phusion polymerase (Thermo 
Science), and nuclease-free water to a final volume of 50 µl.  The solutions were mixed by 
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tapping the PCR tubes before it was collected by a quick centrifugation. Amplification was 
performed with the following cycle conditions in a PTC-200 Peltier Thermal Cycler (VWR): 
first, the initial denaturation at 95°C for 5 min, second, 30 cycles of [denaturation at 95°C for 
30 sec, annealing at 55°C for 30 sec, and elongation at 72°C for 45 sec] third, extension at 
72°C for 5 min. The tubes were kept on 4-10ºC after the PCR. 
The PCR product contained a sequence coding for a hexahis-tag, a TEV cleavage site, 
the blaVIM-7 gene specific sequence (corresponding to A26-E265) and an attB2 site. To inspect 
the whether the amplification was successful or not, an agarose gel electrophoresis method 
was performed. A 0.8% agarose gel was made by weighing out agarose powder and mixed 
with 400 ml of 1x TAE buffer (tris-acetate-EDTA) (Table 1). The agarose solution was 
heated for about 4 min until the solution was dissolved. The melted agarose solution was 
cooled to 60°C before use. Agarose solution containing 0.05% (w/v) RedSafe nucleic acid 
staining solution (ChemBio) was poured into a gel casting tray. The comb was placed in the 
casting tray to generate a row of wells which samples are loaded into once the gel has 
solidified and comb been removed. The samples were added 5 µl 10x TAE loading buffer, 
before loading in to the agarose gel wells. 6 µl of 100 bp DNA Ladder and 6 µl of 1 kb DNA 
Ladder (Invitrogen) were used as DNA standards. 1x TAE buffer was added to the chamber to 
cover the gel, and the agarose gel was run at 90 V for approximately 45 min to separate DNA 
fragments based on size and charge. The PCR product was extracted from the gel and purified 
according to the Ultra-Sep Gel Extraction Protocol (Omega Bio-Tek). 
 The adapter amplification of the product was performed in a second round of PCR to 
include both the Gateway attB1 (from the first PCR) and the attB2 recombination sequences 
for the Gateway cloning. The PCR reaction was performed as previously described, using the 
forward primer 2 (described above) and the same reverse primer as before. The PCR product 
was analysed by agarose gel electrophoresis reaction, as described previously. The DNA was 
extracted and purified described above.  
The PCR product contained an attB1 site, a Shine-Dalgarno part, a start codon, a 
hexahis-tag, a TEV-cleavage site, the blaVIM-7 gene specific sequence (corresponding to A26-








Figure 16: The VIM-7 PCR product used in the Gateway cloning. The PCR product contained an attB1, a 
Shine-Dalgarno sequence to help the ribosome bind the mRNA to initiate protein synthesis, a start codon (ATG) 
for translation, a hexahis-tag (His-tag), a TEV-cleavage site, a blaVIM-7 gene specific sequence (corresponding to  
A26-E265, here termed VIM-7 gene) , a stop codon (TAA) to end translation, and an attB2 sites. The attB1 and 
attB2 sites contribute in incorporating the gene in the entry clone in the Gateway cloning system.  
 
The cloning was performed according to the Gateway cloning protocol (Life 
Technologies) and was initiated by a BP Clonase II reaction [117] [118]. The BP reaction 
contained 150 ng of the purified PCR product, 150 ng donor vector (pDONR221), and TE 
buffer to a final volume of 10 µl (buffer G in Table 1). The recombination reaction was 
incubated at room temperature o/n. 
The BP reaction product was trated with 1 µl Proteinase K, before 2 µl of the reaction 
was transformed to E. coli chemically competent DH5α cells. The cells were incubated with 
DNA on ice for 25-30 min, before heat-shock at 42ºC for 45 sec in a water bath. The cells 
were incubated in 1 ml SOC media (Table 1) at 37ºC for 1 hour, before the cells were pellet 
by centrifugation at 13 000 rpm at room temperature, and spread on a Lysogeny Broth (LB)-
agar (Table 1) plates containing 10 mg/ml kanamycin (Kan) antibiotic. The plates were 
incubated at 37 ºC o/n. 
Mini cultures were prepared of a few (2-5) colonies from the transformation, and 
grown in 3 ml Terrific Broth (TB) media (Table 1) with 10 mg/ml Kan. The mini cultures 
were grown at 37ºC o/n at 250 rpm shaking. Plasmids from the mini cultures were purified 
according to the ZR Plasmid Miniprep-Classic Protocol (Zymo Research) [119].  
A PCR screen was performed to analyse whether the recombination to donor vector 
was successful. The PCR contained 1x Thermo polymerase buffer (Thermo), 2 mM MgSO4, 
200 µM dNTP mix, 0.3 µM M13 forward and reverse primers, 100 ng genomic DNA, 0.02 
U/µl VENT DNA polymerase (Bio Labs), and nuclease-free water to a final volume of 25 µl. 
The PCR cycles were as described above. The PCR product was analysed with agarose gel 
electrophoresis, as previously described.  
The mini cultures that indicated a correctly recombined VIM-7 pDONR221 product, 
shown by PCR screens and electrophoresis with a product of approximately 1000 bp, was 
Sanger sequenced. The sequencing PCR reaction contained the chemicals; 1x sequencing 
buffer, 3.2 pmol of either the M13 forward or the M13 reverse primer, 1x BigDye v3.1, 200 
ng template, and nuclease-free water to a final volume of 20 µl. The PCR setup was with the 
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following cycle conditions in a PTC-200 Peltier Thermal Cycler (VWR); first, the initial 
denaturation at 96°C for 5 min, second, 25 cycles of [denaturation at 96°C for 10 sec, 
annealing at 50°C for 5 sec, and elongation at 60°C for 4 min]. The tubes were kept on 4-10ºC 
after the PCR. The sequencing products were sent to the University Hospital of Northern 
Norway [120]. The returned sequences were analysed and confirmed using the program 
BioEdit Sequence Alignment Editor Version 7.0.9.0 [121]. 
After the sequences were verified the cloning was continued with a LR Clonase II 
reaction performed according to the Life Technologies Protocol [118]. The LR reaction 
contained 100 ng entry clone (the VIM-7 pDONR221), 150 ng/µl pDEST14 destination 
vector, and TE buffer (buffer G in Table 1) to a final volume of 10µl. The LR reaction was 
treated with proteinase and transformed into E. coli cell DH5α, as described above. Mini 
cultures were set up with colonies from the agar-plate in TB-media containing 100 mg/ml 
Amp and 35 mg/ml Cam at 37°C o/n. The mini cultures were purified according to the ZR 
Plasmid Miniprep-Classic Protocol (Zymo Research) [119], described above. Finally, a PCR 
screen was performed as described above, but using T7 promoter and T7 terminator primers. 
The PCR product contained a start codon, hexaHis-tag, TEV cleavage site, the VIM-7 gene 
(A26-E265), and a termination codon (Figure 17). 
The products were analysed by agarose gel electrophoresis, as previously described, to 
verify correct recombination into the pDEST14 vector. The cloning of VIM-7 wt into 




Figure 17: The VIM-7 gene recombined into the expression vector pDEST14 by the Gateway cloning 
system. The his-tag and TEV-cleavage site is intact to facilitate purification of the target protein, and a start 




Point mutations in the VIM-7 wt pDEST14 construct 
Forward and reverse oligonucleotide primers, one pair for each of the three point 
mutations leading to substitution of D120A, D120N and H224Y in VIM-7 wt, were designed. 
The site-directed mutagenesis was performed by using the Quikchange Lightning Site-
Directed Mutagenesis Kit protocol (Stratagene).  The mutations were incorporated into the 
VIM-7 wt-pDEST14 construct by a PCR. The sequencing PCR protocol is described above. 
The paternal plasmid DNA was removed according to the Quikchange Site-Directed 
Mutagenesis Kit (Stratagene) by adding 1 µl DpnI restriction enzyme to the mutagenesis 
reaction and incubated at 37ºC for 1 hour. Incubation at 72ºC for 10 min inactivated the DpnI. 
The pDEST14 vector specific PCR colony screens were performed to find clones encoding an 
approximately 1000 bp product, as previously described. The PCR reaction was performed by 
using T7 promoter and T7 terminator primers. Results were analysed with agarose gel 
electrophoresis, as previously described, before positive clones were analysed with Sanger 
Sequencing, as described above. 
The mutagenesis primers constructed are as follows, where the red lower case letter 
shows the mutation and red colour shows codons: 
 
VIM-7 D120A fwd 
5’-TTCCATGACGcTCGAGTCGGTGGAGTTGATGTCCTCCGGGCGGCT-3’ 
 
VIM-7 D120A rev 
5’- ACCGACTCGAgCGTCATGGAAGTGCGTAGAAATTGAGCGCGTTAC-3’ 
 
VIM-7 D120N fwd 
5’-TTCCATGACaATCGAGTCGGTGGAGTTGATGTCCTCCGGGCGGCT-3’ 
 
VIM-7 D120N rev 
5’-ACCGACTCGATtGTCATGGAAGTGCGTAGAAATTGAGCGCGTTAC-3’ 
 
VIM-7 H224Y fwd 
5’-TGTGCAGTTtATGAGGCGTCACGCGAATCCGCGGGTAATGTTGCC-3’ 
 





Preparation of Z-competent cells of Rosetta2(DE3)pLysS and 
BL21(DE3)star/pRARE/pLysS 
 Z-competent E. coli cells are, by a method developed by Zymo Research, made 
chemically competent that completely eliminates the need for heat shock and related 
procedures. Z-competent E. coli are chemically competent cells used for simple and efficient 
DNA transformation. 
Glycerol stocks of Rosetta2(DE3)pLysS (Novagen) and 
BL21(DE3)star/pRARE/pLysS (Novagen) were each spread on different LB-agar plate (Table 
1) containing 34 µg/ml Cam and incubated at 37°C overnight (o/n). Single colonies of 
Rosetta2(DE3)pLysS and BL21(DE3)star/pRARE/pLysS cells from the LB-agar plates were 
each inoculated into 1 ml SOB media (Table 1) and incubated at 37°C o/n. 50 ml SOB 
containing 34 µg/ml Cam were inoculated with 1:100 pre-culture Rosetta2(DE3)pLysS or 
BL21(DE3)star/pRARE/pLysS. The mini culture was incubated to reach a cell density (OD) 
of log phase (0.4-0.6). The cultures were cooled on ice for 10 min, before pelleting the cells 
by centrifugation at 4°C at 3500 rpm for 10 min. The pellet was washed in 5 ml cold 1x Wash 
Buffer, and collected as described above. The pellet was gently resuspended in 5 ml 1x 
Competent Buffer. Wash and Competent buffer were from the Z-Competent E. coli 
Transformation Kit & Buffer Set (Zymo Research) [122]. Finally, the cells were distributed in 
100 µl aliquots in pre-frozen eppendorf tubes, and stored at -70°C. 
 
Protein expression of recombinant VIM-7 wt and mutants 
In order to test what strain was most optimal to use in production of the proteins, a 
small scale expression experiment was set up for testing the recombinant VIM-7 wt-pDEST14 
and the three mutants in both E. coli Rosetta2(DE3)pLysS and E. coli BL21 (DE3) 
star/pRARE/pLysS. The small scale expression of the cells were performed in 20 ml LB-
media (Table 1) containing 100 mg/ml Amp and 34 mg/ml Cam, and were grown at 37ºC to 
reach log phase OD 600 0.5-0.7. The expression was induced at different temperatures; 37ºC 
for 4 hours and 20ºC o/n, with 0.4 mM Isopropyl-β-D-1- thiogalactopyranoside (IPTG).  
For large scale protein expression, the three different mutants of VIM-7 were 
expressed in E. coli Rosetta2(DE3)pLysS cells with the use of two litres times 1 LB-media 
(Table 1) with 100 µg/ml Amp and 34 µg/ml Cam. The cultures were grown at 37°C, and the 
growth was monitored by measuring the cell density at OD 600 nm in a spectrophotometer to 
reach a value of 0.5-0.7. The cultures were then induced with 0.4 mM IPTG and grown at 
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either at 20°C o/n or at 37ºC for 4 hours. The cells were harvested by centrifugation at 5000 
rpm for 18 min at 4°C in a Beckman Avanti centrifuge. The culture media was discarded, and 
the pellets frozen at -20°C for later use.  
 
Cell disruption 
Each pellet from the large scale protein expression was resuspended in 30 ml buffer A 
(Table 1) together with one tablet of SigmaFAST EDTA-free protease inhibitor cocktail 
(Sigma). The cells were disrupted by sonication for 9.9 sec pulses with amplitude of 25%, a 
max temperature of 8°C for 35 min by the Vibra-Cell sonicator (Sonics). The supernatant of 
the sonication product containing soluble proteins was obtained by centrifuging at 14.000 rpm 
for 30 min at 4°C. 
 
SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to analyse the protein expression and quality after each purification steps. After purification, 
SDS-PAGE analysis was performed in order to choose fractions for further analysis. Fractions 
were loaded on 4-20% Mini-PROTEAN TGX Precast Gels (Bio-Rad) and performed 
according to the protocol [123]. 25 µl of the purification fractions for SDS-PAGE analysis 
were pooled and 10 µl of 3xSample buffer (SB) were added. 1x SB consists of 4xNuPage 
LDS Sample buffer (Invitrogen), 100 µl MilliQ water and 150 µl 14.3 M BME. To denature 
proteins, all gel samples were boiled at 95ºC for 3-5 min before they were loaded onto the gel. 
Routinely, 5 µl of Mark12 Unstained Standard (Invitrogen) was used as a molecular weight 
marker. 10 µl of the protein samples were loaded to the gel. The gel was in a 1xTris-Glycine 
buffer at 200 V, 90 mA and 12.5 W for about 40 min. The gel was rinsed three times with 
MilliQ water, and heated in a microwave oven in between. The water was discarded before 
adding 20-30 ml SimpleBlue SafeStain (Invitrogen) to the gel. The gel was again heated as 
described before and placed on an orbital shaker for 15-60 min. The stain was then discarded, 





 In order to separate the VIM-7 proteins, which are tagged with a hexahistidine tag, 
from the other E. coli proteins, affinity purification is performed. Histidine tags have an 
affinity for nickel or cobalt ions. Imidazole is used for elution, because of its ability to act as a 
metal ion ligand. The VIM-7 proteins are separated from other untagged protein, the 
hexahistidine tag is cleaved off in dialysis, and the VIM-7 proteins are separated from the 
tagged proteins in the second affinity purification step. 
For the purification a 1 ml HisTrap High Performance (HP) column, the ÄKTA 
explorer Fast Protein Liquid Chromatography (FPLC) system and the computer program 
Unicorn 5.0 (GE Healthcare United Kingdom) were used. The buffers used in the affinity 
purification were the buffer B and the buffer C (Table 1). The flow rate was set to 1 ml/min 
and the maximum pressure set to 0.5 MPa. The lysate were loaded onto a 50 ml super loop 
connected to the ÄKTA explorer FPLC system. To prepare the 1 ml HisTrap HP column, it 
was first washed with 20% ethanol, then with ddH2O, and finally with buffer B (Table 1). The 
purification was done with loading the lysate with buffer B (Table 1) over 17-42 column 
volumes (CV), before a 10 mM-1 M imidazole gradient over 15 CV, and the size of the eluate 
fractions collected were 1 ml. 
 
TEV cleavage by dialysis 
 Dialysis was used to perform the TEV protease cleavage of the hexahistidine tag 
attached. TEV is named after where it was found, the Tobacco Etch Virus, and the TEV 
protease is a highly site-specific enzyme. TEV recognise the amino acid sequence 
ENLYFQ(G/S), and performs a cleavage between the Q and G/S residue [124]. Dialysis is a 
purifying step, in a way that it separates the molecules in the solution according to their 
ability to diffuse through a semi permeable membrane with different cut offs. Small 
molecules like salt, water and such, move through the membrane in the direction of 
decreasing concentration.  
The selected fractions from the HisTrap purification, which from the SDS-PAGE 
indicated the target protein, were pooled for dialysis with TEV protease. The fractions, 
together with TEV protease, with a TEV concentration of 1:100 of the protein concentration 
[125], were injected in the Slide-A-Lyzer Dialysis Casette (Extra strength); cut off 10 kDa 
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(Thermo Sciences). The dialysis buffer D (Table 1) was used during the dialysis, and the 
dialysis was performed o/n at 4°C. 
 
Gel filtration of VIM-7 H224Y mutant 
 Gel filtration is a size-exclusion chromatography method, where the molecules in the 
solution are separated by size. The motivation for this purification method was to get as pure 
protein as possible for the enzyme kinetic studies. 
Gel filtration was carried out on an ÄKTA Explorer FPLC system using a Hiload 
16/60 200 prep grade Superdex column (Amersham Bioscience), with maximum pressure of 
0.5 MPa and flow rate of 1.5 ml/min. The buffer A (Table 1) was used for gel filtration. 
 
Protein concentration measurement 
The Nanodrop 2000c Spectrophotometer (Thermo Sciences) was used to measure the 
protein concentrations, in order to calculate the amount of protein in the samples. 1 µl of 
buffer B (Table 1) was used as blank, and 1 µl of protein sample was used during the 
measurement, when measuring protein concentration after affinity purification. The gel 
filtration buffer A (Table 1) was used as blank for measurements after gel filtration. By using 
the online program Protparam at ExPasy [126], the molecular weight and the extinction 
coefficient was determined, based on the sequence.  
 
Table 2: Extinction coefficient and molecular weight of the proteins VIM-7 wt, VIM-7 D120A and VIM-7 
H224Y as determined by Protparam (ExPASy) [126]. 
Protein Extinction coefficient, Δε Molecular weight (Da) 
VIM-7 wt 26 930 25 591.8 
VIM-7 D120A 26 930 25 547.8 





 To determine whether VIM-7 wt, VIM-7 D120A and VIM-7 H224Y are receptive to 
the action of specific antibiotic, the Epsilometer test (E-test) was performed. The E-test is 
based on a LB-agar medium inoculated with the test organism and the diffusion of a microbial 
gradient from a coated plastic strips into the agar. Directly from the scale on the strips the 
minimum inhibitory concentrations (MIC), which are the zone where the growth inhibition 
intersects the strip, are read [127]. This laboratory test is common in medicine, where the 
medical doctor is seeking guidance in the concentration of the antibiotics and which antibiotic 
is suitable for the patient. The enzymes were transformed into E. coli Rosetta2(DE3)pLysS 
cells, and they were spread on LB-agar plates containing 100 µg/ml Amp and 35 µg/ml Cam, 
and incubated at 37ºC o/n. Single colonies were inoculated in a water solution containing 
NaCl, for the solution to obtain a cell density of 0.5. Cotton sticks were dipped in the solution 
containing protein, and a cross was streaked on a LB-agar plate, before the solution was 
spread on the whole plate by rotating it and moving the cotton stick towards the middle and 
back. Rectangular strips, E-tests (bioMérieux, Marcy l’Etoile), containing increasing 
concentration of selected antibiotics; ertapenem, meropenem, imipenem, cefuroxime, 
ceftazidime, cefoxitin, piperacillin, aztreonam, and amoxicillin, were placed on the agar plate 
with the protein solution and incubated at 37ºC over night. The MIC of the proteins was read 
by researcher Ørjan Samuelsen at University Hospital of Northern Norway the next day. 
 
Activity testing by using nitrocefin 
 In order to test the VIM-7 wt and the mutants D120A and H224Y for their activity, the 
substrate nitrocefin (Merck) was used in a colorimetric enzyme assay. Nitrocefin changes 
colours from yellow to red, when there is an active enzyme present. The nitrocefin hydrolysis 
the product and can be detected spectrophotometrically at 482 nm. The measurements were 
performed on a UV spectrophotometer SpectraMax M2e (Molecular Devices) and analysed 
with the SoftMax Pro 5.2 software (Molecular Devices). In this assay, the proteins were used 
with a concentration of 0.1 µM made by diluting it in an enzyme kinetic buffer F (Table 1). 
The presence of Bovine Serum Albumin (BSA) in the enzyme stock solution protects the β-
lactamases from denaturation at low protein concentration, and allows for reproducible and 
reliable measurements of the initial rate of enzyme-catalyzed hydrolysis of the substrate [128]. 
The nitrocefin concentration was 100 µM in all assays. Directly before starting the experiment, 
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10 µl protein solution was mixed with 40 µl of 100 µM nitrocefin and 50 µl of enzyme kinetic 
buffer E (Table 1). The temperature used during the measurements was 25°C. 
 
Enzyme kinetics 
In order to measure the specific efficiency of the enzymes VIM-7 wt, VIM-7 D120A 
and VIM-7 H224Y, enzyme kinetics studies were performed. The specific efficiency 
represents the ability of the enzyme to convert substrate into product. 
The antibiotics ertapenem, meropenem, cefuroxime, ceftazidime, cefepime and 
cefoxitin were dissolved in buffer E (Table 1). The substrates concentration of the stock 
solutions were determined by measuring the absorbance by using the spectrophotometer and 
the software described above, and the extinction coefficient of each substrate (Table 3). The 
solutions for kinetic analyses were made in the range of 2-1000 µM for each antibiotic. 
 The proteins VIM-7 wt, VIM-7 D120A and VIM-7 H224Y were diluted in buffer F 
(Table 1). The absorbance of the substrate nitrocefin was measured at 482 nm in a 96-well flat 
bottom non-binding surface plate, while the absorbance of the other substrates was measured 
using 96-well falcon UV microplates. This is because the antibiotics, apart from nitrocefin, 
interact with the plastic in the non-binding surface. 
 
Table 3: Extinction coefficients, plate-specific extinction coefficients, and wavelengths for the substrates 








Nitrocefin 17400 0.00645 482 
Ertapenem -6920 0.00710 300 
Cefuroxime -7600 0.00252 260 
Ceftazidime -9000 0.00431 260 
Cefepime -10000 0.00392 260 
Cefotixin -7700 0.00231 260 
Meropenem -6500 0.00306 300 
 




Crystallization of VIM-7 H224Y mutant 
Crystallization trials were set up with the hanging drop method [129] for the VIM-7 
H224Y mutant, using a protein concentration of 17 mg/ml and a reservoir solution with 20-
25% polyethylene glycol monomethyl ether 2000, 0.1 M calcium acetate, 0.1 M sodium 
cacodylate pH 5.0 with 8 mM BME [29]. Each drop formulation was made by mixing 1 µl of 
17 mg/ml protein and 1 µl of reservoir solution, with a reservoir volume of 500 µl. The plates 
were stored at room temperature. 
Additionally, trials were also set up with the Phoenix DT crystallization robot (Rigaku) 
with the sitting drop method [130]. The screen used, named KCSG, was made by researcher 
Kenneth Johnson (Norstruct, Uit). In the sitting drop method the drops contained 200 nl of 
VIM-7 H224Y protein and 200 nl of reservoir solution, and the wells contained 60 µl 
reservoir solution. The trials were stored at room temperature. 
A crystal of the VIM-7 H224Y mutant obtained from the robot was cryoprotected by 
researcher Hanna-Kirsti Schrøder Leiros, and sent to Max-LAB in Lund, Sweden for x-ray 
data collection. The crystal structure refinement was performed by researcher Hanna-Kirsti 
Schrøder Leiros. The antibiotic substrate Ceftazidime was docked into the crystal structure of 
the VIM-7 H224Y mutant, in silico, by using the molecular visualization program PyMOL. 
The docking was performed using the structure of the VIM-7 (PDB ID: 2Y87 [29]), which 
















Cloning and mutagenesis of VIM-7 wt 
 The blaVIM-7 gene originated from P. aeruginosa [42], subcloned into pET26b(+) 
vector by Samuelsen et al [43], was successfully cloned into the expression vector pDEST14 
performed using the Gateway cloning system. First, the blaVIM-7 gene, corresponded to amino 
acid sequence A26-E265, was cloned to contain an N-terminal hexahis-tag and a TEV 
cleavage site, an attB and an attB2 recombination site for the Gateway system, and start and 
termination codon (Figure 16). Then the blaVIM-7 gene was cloned into the donor vector 
pDONR221 in a BP Clonase II reaction. The blaVIM-7 sequence was verified by Sanger 
sequencing, before the gene was cloned into the expression vector pDEST14 in a LR Clonase 
II reaction. The new gene contained the N-terminal hexahis-tag, a TEV cleavage site and start 
and termination codons (Figure 17). The cloned gene of blaVIM-7 sequence was called “VIM-7 
wt”.  
Three different site-directed mutations, VIM-7 D120A, VIM-7 D120N and H224Y, 
were successfully performed by using the Quikchange Lightning Site-Directed Mutagenesis 
Kit (Stratagene). To screen for positive mutation clones, T7 forward and reverse vector-
specific primers were used in a Phusion PCR reaction to amplify fragments of correct size, an 
approximately 1000 bp product (Figure 18). The PCR screens were used to select clones for 
Sanger sequencing. The PCR products were separated by size and charge on a 0.8% (w/v) 
agarose gel prestained with 0.05% RedSafe DNA stain. As a references for estimating the size 
of DNA fragments, both 100 bp DNA Ladder and 1 kb DNA Ladder were used as DNA 
markers. Positive control with pDEST14 and negative control (without plasmid) were also run, 
to make sure that the PCR screening was performed without complications. The positive 





Figure 18: PCR screening of positive a) VIM-7 D120A mutants, b)VIM-7 D120N mutants, and c)VIM-7 
H224Y mutants, all in pDEST14 expression vector. PCR using vector-specific T7 primers were performed to 
screen for positive VIM-7 mutant clones in pDEST14 vector. PCR products were size separated by agarose gel 
electrophoresis. Agarose gel analysis showing; 100 bp DNA marker (M1), 1 kb DNA Ladder (M2). Relevant 
marker bands are indicated by size (bp) on the left and the right side of the gel image, and positive amplification 
of VIM-7 mutants are indicated with an arrow. a) Positive control amplification of a 2030 bp product from 
pDEST14 (lane 2), VIM-7 D120A mutant amplification (lane 3), and negative control without DNA template 
(lane 4). b) VIM-7 D120N mutant amplification of individual clones (lane 2,3 and 4), positive control 
amplification of a 2030 bp product from pDEST14 (lane 5), negative control without DNA template (lane 6).  
c) VIM-7 D120N mutant amplification (lane 1). 
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The VIM-7 wt was sequenced after cloning in the donor vector pDONR221 in the 
Gateway cloning system. The VIM-7 wt was then recombined from donor vector pDONR221 
to the expression vector pDEST14, but the cloning product was not sequenced to the 
expression vector. The mutants were sequenced both in forward and reverse direction, and the 
mutants were in the expression vector pDEST14.  
According to the agarose electrophoresis gel analysis of the VIM-7 D120N mutant, an 
approximately 1000 bp product is weakly visible for two of three amplification reactions 
(Figure 18b, lane 2 and 4). All three were sent for sequencing, and only one plasmid 
contained the correct sequence. Lane 2 (Figure 18b) had insertions as analysed by Sanger 
sequencing, and was not used further.  
 Clones containing the desired mutations, D120A, D120N and H224Y were identified 
by PCR screenings and by Sanger sequencing. T7 primer specific amplifications from the 
VIM-7 D120N pDEST14 plasmid are not as clear. The VIM-7 D120A pDEST14 plasmid and 
the VIM-7 H224Y pDEST14 plasmid were amplified as expected.  
 
Figure 19: Chromatogram selections of the sequences of VIM-7 wt compared to the mutants. a) VIM-7 wt 
sequence (showing only amino acids D119-G123) as it is cloned into the pDONR221 vector compared to the 
VIM-7 D120A mutant (middle panel) and the VIM-7 D120N mutant (lower panel), both of the latter sequences 
in the pDEST14 vector. b) VIM-7 wt sequence (showing only amino acids V223-S227) in the pDONR221 






 The peaks in the chromatogram show that the VIM-7 D120N mutants are not as 
distinct as the peaks in the VIM-7 wt and the VIM-7 D120A mutant (Figure 19a). For Sanger 
sequencing the read lengths are routinely 800-1200 base pairs long [131]. The read length of 
the sequence encoding VIM-7 D120N is approximately 500 base pairs. With a short read 
length like this, the mutant is near the end of the sequence, and the sequencing intensity is not 
as strong as it would have been in with a longer reading length. An overload of DNA template 
might lead to a large number of small fragments [132]. 
 To conclude, the mutagenesis for all three point mutations was performed successfully, 
and the mutations were all confirmed by Sanger sequencing. 
 
Small and large scale protein expression  
To find out whether the recombinant VIM-7 wt and the mutant proteins, containing a 
hexahis-tag and a TEV cleavage site, were inducible with 0.4 mM IPTG from the pDEST14 
vector, two different E. coli strains were used, and induced at two different temperatures, 
37ºC and 20ºC. The strains used were Rosetta2(DE3)pLysS and 
BL21(DE3)star/pRARE/pLysS strains, and the temperatures of induction was 37°C for 
approximately 4 hours, or 20°C o/n, respectively (data not shown). The VIM-7 wt, VIM-7 
D120A mutant and VIM-7 H224Y mutant were induced by both E. coli strains, and 
Rosetta2(DE3)pLysS was chosen for large scale protein expression. 
 
 
Figure 20: SDS-PAGE analysis of recombinant protein expression of VIM-7 wt and mutant VIM-7 D120N 
at different temperature in Rosetta2(DE3)pLysS. SDS-PAGE analysis with the protein marker Mark12 
(Marker), showing molecular weight band values to the left (as kilodaltons, kDa). Lane 1-3 shows VIM-7 wt; 
lane 1) before induction with 0.4 mM IPTG, lane 2) was after induction at 37°C for 4 hours, and lane 3) after 
induction at 20°C o/n. Lane 4-6 shows VIM-7mutant D120N; lane 4) before induction with 0.4 mM IPTG, lane 
5) after induction at 37°C for 4 hours, and lane 6) after induction at 20°C o/n. The strain Rosetta2(DE3)pLysS 




 The recombinant VIM-7 D120N mutant was, however not inducible (lane 5 and 6, 
Figure 20). The experiment was repeated three times, however, with unsuccessful results. 
Several buffers were used in order to check solubility, and the VIM-7 wt and the VIM-7 
D120A and H224Y mutants were soluble in all of the buffers (data not shown).  
The VIM-7 wt, VIM-7 D120A and VIM-7 H224Y mutants were expressed in both 
strains and at both temperatures to an equal level (data not shown). 
In order to check whether the VIM-7 D120N mutant was observable in large scale, it 
was attempted to produce in large scale. The VIM-7 wt, VIM-7 D120A and VIM-7 H224Y 
mutants were all produced successfully in 1 litre large scale expression in 
Rosetta2(DE3)pLysS, while the VIM-7 D120N mutant was expressed, even in large scale 
production.  
 
Purification of VIM-7 wt, VIM-7 D120A and VIM-7 H224Y 
To perform kinetics studies and set up crystallization trials, the proteins VIM-7 wt and 
the mutants were purified. The pellets containing the Rosetta2(DE3)pLysS with the target 
protein were dissolved in lysis buffer A (Table 1), before they were disrupted by sonication 
for the proteins to exit the cells. Purification was done by the affinity purification method 
[113] using a HisTrap HP 1 ml column with a flow rate of 1 ml/min, and a pressure of 0.5 
MPa. The column was washed, and the lysate was loaded to the column. The buffer B (Table 
1) was used on the column over 17-42 CV for the absorbance 280 to decrease before an 
imidazole gradient ranging from 10 mM-1M was used to elute the protein, by using buffer C 
(Table 1). The flowthrough was collected as 5 ml fractions, while the elution fractions were 
collected as 1 ml fractions. HisTrap purification method was performed before and after 
dialysis with TEV cleavage.  
Based on analysis of the VIM-7 D120A mutant and the VIM-7 H224Y mutant amino 
acid sequences, the mass was expected to be about 26 kDa (Table 2), and the induced proteins 








Purification of VIM-7 wt 
 
 
Figure 21: Affinity purification and SDS-PAGE analysis of VIM-7 wt. a) HisTrap purification with a 10-
1000 mM imidazole gradient using a HisTrap HP 1 ml column over 15 CV with a flow of 1 ml/min and a 
collection of 1 ml fractions. The blue line indicates the absorbance at 280 nm and the green line indicate the 10-
1000 mM imidazole gradient. The different peaks are marked with arrows, and the fractions are marked in red 
along the x-axis, while the absorbance is marked along the y-axis. The pink line shows injection of sample. b) 
The SDS-PAGE shows selected fraction from the HisTrap purification in a). The marker used is Mark12 
Unstained Standard (Life Technologies), soluble fraction after sonication (lane 1), resuspended pellet after 




 The elution peak of VIM-7 wt in the affinity purification chromatogram has a value of 
ca. 700 mAU (Figure 21a). The flowthrough fractions 1-6 were all pooled. Selected fractions 
from all steps of the purification were analysed by SDS-PAGE (Figure 21b). 
The fractions 20-23 (lane 4-7, Figure 21b) were dialysed in a dialysis buffer D (Table 
1) o/n with a magnetic stirrer at 4°C, with TEV (1:100 of protein concentration) added to the 
protein sample. To know the amount of protein in the fractions, the protein concentration was 
measured by Nanodrop. The VIM-7 wt protein concentration was 1.2 mg/ml before dialysis 
and TEV cleavage. 
 
Affinity purification of VIM-7 wt was repeated after TEV digestion with the same 
conditions as earlier. The imidazole gradient was from 10-1000 mM over 15 CV, and in this 
purification, TEV, his-tagged TEV and other his-tagged proteins are eluted in the gradient. 
The cleaved VIM-7 wt protein is eluted in the flowthrough because of its inability to bind to 











Figure 22: Affinity purification of VIM-7 wt and SDS-PAGE analysis after dialysis with TEV cleavage.  
a) HisTrap purification after dialysis and TEV cleavage with a 10-1000 mM imidazole gradient using a HisTrap 
HP 1ml column. The first two fractions were 5 ml. The blue line shows the absorbance at 280 nm and the green 
line displays the imidazole gradient. The different peaks are marked, and the fractions are marked in red along 
the x-axis, while the absorbance is marked along the y-axis. The pink line shows injection of sample. b) SDS-
PAGE showing selected fraction from the HisTrap purification in a). The marker used is Mark12 Unstained 
Standard (Life Technologies), flowthrough fraction 1 (lane 1), flowthrough fraction 2 (lane 2), flowthrough 
fraction 3 (lane 3), fraction 15-20 (lane 4-9), fraction 29 (lane 10), fraction 30 (lane 11). TEV and VIM-7 wt are 




 The peak of the VIM-7 wt had a maximum absorbance of 185 mAU (Figure 22a), 
verified by the SDS-PAGE analysis (Figure 22b). The VIM-7 wt was eluted in the 
flowthrough. TEV which contain his-tags and proteins, including VIM-7 wt, with his-tags still 
attached, eluted in the imidazole gradient.  
 The flowthrough fractions 1-3 (lane 1-3 in Figure 22b) all contained the VIM-7 wt 
protein, and were pooled. The protein concentration of the pooled fractions was 0.28 mg/ml, 
as determined by NanoDrop. The pooled fractions of 1-3 (lane 1-3, Figure 22b) were 
estimated to be reasonably pure. The fractions (lane 6-9, Figure 22b) from the peak in the 
gradient (Figure 22a), all contained TEV which had a mass of about 33 kDa. TEV and 
uncleaved VIM-7 wt in the SDS-PAGE analysis is observed in fractions 16-20 (Figure 22b) 
above the VIM-7 wt protein. 
 The affinity purification of VIM-7 wt was successful, and the pooled fractions of 
VIM-7 wt protein had a protein concentration of 0.28 mg/ml were estimated to be pure 
enough to perform the enzyme kinetic studies.  
 
Purification of VIM-7 D120A mutant 
 The procedure for the purification of VIM-7 mutant D120A was identical to the 






Figure 23: Affinity purification and SDS-PAGE analysis of VIM-7 mutant D120A. a) HisTrap purification 
using a HisTrap HP 1ml column. The blue line indicates the absorbance at 280 nm and the green line indicates 
the imidazole 10-1000 mM gradient. The different peaks are marked with arrows. The pink line shows injection 
of sample. b) SDS-PAGE showing selected fraction from the HisTrap purification. Sample from before 
sonication (lane 1), after sonication (lane 2), flow through fraction 1 (lane 3), flow through fraction 2 (lane 4), 
fraction 20-26 (lane 5-11). The marker used is Mark12 Unstained Standard (lane 12 as Mark12), and the masses 




 As for the purification of VIM-7 wt, the flowthrough fractions 1-7 were pooled and 
the SDS-PAGE analysis was performed. The peak of VIM-7 D120A mutant has an 
absorbance of maximum 500 mAU (Figure 23a), and was showed by SDS-PAGE analysis 
(Figure 23b). The target protein migrates according to its expected mass.  
 The fractions 22-26 (lane 7-11, Figure 23b) were pooled, TEV protease was added, 
and they were set for dialysis with TEV-cleavage o/n at 4ºC in a dialysis buffer D (Table 1). 
The protein concentration of the pooled fractions before dialysis was 1.3 mg/ml as measured 






Figure 24: Affinity purification and SDS-PAGE analysis of VIM-7 D120A mutant after dialysis and TEV 
cleavage.  a) HisTrap purification after TEV cleavage with a 10-1000 mM imidazole gradient (green line) using 
a HisTrap HP 1ml column. The first two fractions were 5 ml. The blue line indicates the absorbance at 280 nm 
(mAU). The different peaks are marked, and the fractions are marked in red along the x-axis, while the 
absorbance is marked along the y-axis. b) SDS-PAGE analysis showing selected fraction from the HisTrap 
purification after dialysis and TEV cleavage. The marker used is Mark12 Unstained Standard, sample after 
dialysis before purification (lane 1), flow through fraction 1 (lane 2), flow through fraction 2 (lane 3), fraction 4-




 The peaks with absorbance of 80, 95 and 30 mAU in fractions 1-6 (Figure 24a) shows 
from the SDS-PAGE analysis (Figure 24b) consistent in size to be the VIM-7 mutant D120A. 
There is not one consistent peak for the protein; this may be because of the pump changing 
the pressure on the column. After fraction 2, some protein appears to have been directed to 
waste, which causes the peak to drop to 15 mAU before the rest of the protein was injected 
into the column. The peaks at fraction 16-22 (Figure 24a) are his-tagged TEV, uncleaved 
VIM-7 D120A mutant and other proteins which have not cleaved off the His-tag, and the 
peaks have an absorbance of 85 and 110 mAU. 
 The flowthrough fractions 1 and 2 and fraction 4-6 (lane 2-6, Figure 24b) were pooled, 
and estimated to be reasonably pure for enzyme kinetic studies. Gel filtration purification was 
not performed, because it would reduce the total yield of the protein. A considerable amount 
of uncleaved VIM-7 D120A is in the fractions with TEV along with other proteins (lane 10-
12, Figure 24b), due to insufficient amounts of TEV added to the dialysis to perform the 
TEV-cleavage.  
 The protein concentration of the pooled fractions lane 2-6 (Figure 24b) was 0.2 mg/ml. 
To use the protein for enzyme kinetics studies the fractions were pooled and concentrated 
with a Millipore centrifugal filter. The protein concentration of the fractions after up 
concentration was 7.8 mg/ml. 
 The TEV cleaved VIM-7 D120A mutant was successfully affinity purified, and the 
protein concentration estimated to 7.8 mg/ml, with estimated to be reasonable pure for further 
enzyme kinetic studies. 
 
Purification of VIM-7 H224Y mutant 
 The procedure for the affinity purification and dialysis of VIM-7 mutant H224Y was 





Figure 25: Affinity purification and SDS-PAGE analysis of VIM-7 H224Y mutant. a) HisTrap purification 
with a 10-1000 mM imidazole gradient (green line) using a HisTrap HP 1ml column over 15 CV with a flow of 
1 ml/min and a collection of 1 ml fractions. The blue line shows the absorbance at 280 nm. The fractions are 
marked in red along the x-axis, while the absorbance is marked along the y-axis. The pink line shows injection of 
sample. b) SDS-PAGE analysis showing selected fraction from the first HisTrap purification of VIM-7 H224Y 
mutant. The molecular weight marker used is Mark12 Unstained Standard, before induction (lane 1), after 
induction (lane 2), before sonication (lane 3), after sonication supernatant (lane 4), after sonication pellet (lane 5), 




The peak of VIM-7 H224Y mutant has absorbance of 2944 mAU (Figure 25a). From 
the SDS-PAGE analysis (Figure 25b), it appears to be substantial amounts of VIM-7 H224Y 
mutant in the fractions 23-25 (lane 11-13, Figure 25b) from the peak (Figure 25a). The SDS-
PAGE gel is clearly overloaded. By adding less amount of sample to the gel, the fractions for 
VIM-7 H224Y would be more defined.  
A pink colour of fractions 23 and 24 (Figure 25a) of the VIM-7 H224Y mutant after 
the purification appeared. This is discussed later. The fractions 23-25 (lane 11-13, Figure 25b) 
were pooled, TEV was added, and they were dialysed with TEV-cleavage o/n. To get an 
estimate of the amount protein in the pooled fractions, the protein concentration was 


















Figure 26: Affinity purification and SDS-PAGE analysis of VIM-7 H224Y mutant after dialysis and TEV 
cleavage. a)  HisTrap purification with a 10-1000 mM imidazole gradient (green line) using a HisTrap HP 1ml 
column, was performed after TEV cleavage. The blue line indicates the absorbance at 280 nm. b) SDS-PAGE 
analysis shows selected fraction from the second HisTrap purification of VIM-7 mutant H224Y. The marker 
used is Mark12 Unstained Standard (Mark12), after dialysis (lane 1), flow through fraction 1 (lane 2), flow 





The peaks in fractions 1-4 and fraction 6 (Figure 26a) shows the VIM-7 H224Y 
mutant, as verified by SDS-PAGE analysis (Figure 26b) with a peak at 750 mAU. After 
fraction 2, some protein was directed to waste before injecting the rest of the protein onto the 
column, which causes the peak to drop before increasing again. The peaks at fractions 16-22 
(Figure 26a) are TEV containing his-tags and other proteins with his-tags still attached, with 
peaks at 50 and 150 mAU. 
The SDS-PAGE gel (Figure 26b) is overloaded, and by adding less amount of the 
VIM-7 H224Y mutant sample to the analysis, the target protein would be more defined and 
contaminants (approximately 40-97 kDa) would be less visible. 
The fractions from both flowthroughs and fraction 3 (lane 2, 3 and 4, Figure 26b) were 
pooled, and estimated to be reasonably pure. To further purify and investigate the integrity of 
the protein, gel filtration purification was performed on flowthrough 2 (lane 3) and fraction 3 
(lane 4) pooled. It appears to be some uncleaved VIM-7 H224Y mutant in the elution, 
fractions 17-21, (lane 9-13, Figure 26b) with TEV along with other proteins containing his-
tags.  
 The fraction flowthrough 2 (lane 3) and fraction 3 (lane 4) was pooled and the protein 
concentration was 2.5 mg/ml. The protein concentration of the fraction flowthrough 1 (lane 2) 
was 1.3 mg/ml, and was concentrated by using a Millipore centrifugal filter. The protein 
concentration after up concentration was 20.1 mg/ml. 
The affinity purification of recombinant VIM-7 H224Y mutant was successfully 
performed. Flowthrough 1 (lane 2) was roughly estimated to be 97% pure, and was used to set 
up crystallization trials. To perform enzyme kinetic studies, the flowthrough 2 and fraction 3 
(lane 3-4, Figure 26b) were purified further by gel filtration purification. 
 
Gel filtration of VIM-7 H224Y mutant 
 To perform a gel filtration, a HiLoad 16/60 column was used, with a flow rate of 1.5 
ml/min, and a maximum pressure of 0.5 MPa. The fractions sizes were 3 ml. The buffer used 





Figure 27: Gel filtration purification and SDS-PAGE analysis of VIM-7 H224Y mutant. a) Gel filtration 
purification Superdex HiLoad 16/60 column with a flow of 1.5 ml/min, a maximum pressure of 0.5 MPa and 3 
ml fractions. The blue line indicates the absorbance at 280 nm. The peak is marked, and the fractions are marked 
in red along the x-axis, while the absorbance is marked along the y-axis. The pink line shows injection of sample. 
b) SDS-PAGE gel showing selected fraction from the gel filtration purification of VIM-7 mutant H224Y. The 
marker used is Mark12 Unstained Standard, before gel filtration (lane 1), fraction 22-29 (lane 2-9), fraction 33 




The peak in fractions 26-28 (Figure 27a) with a value of 190 mAU was analysed on a 
SDS-PAGE gel, which showed that is was the VIM-7 H224Y mutant. In order to confirm that 
the VIM-7 H224Y mutant is purer than before the gel filtration purification a SDS-PAGE 
analysis was performed on the selected fractions 22-29, 33 and 38. The analysis was 
performed with a sample of the VIM-7 H224Y mutant before gel filtration purification for 
comparison (lane 1, Figure 27b).  
The shoulder (Figure 27a) might be a multimer or aggregates of the protein [133], 
which is shown in lane 2-5 (Figure 27b).  
 The protein was purer after gel filtration, and was considered reasonably pure. The 
fractions 26-28 (lane 6-8) were pooled and protein concentration measured to be 0.3 mg/ml. 
The pooled fractions were up concentrated to be 3.3 mg/ml. The protein from the gel 
filtrations was used further in the enzyme kinetics studies. 
 The purification of VIM-7 H224Y mutant was successfully, both for the affinity 




















Epsilometer tests  
 The E-test was performed to study whether the VIM-7 wt, the VIM-7 D120A and the 
VIM-7 H224Y enzymes are receptive to specific antibiotics. 
The results were read by researcher Ørjan Samuelsen, but the results showed no 
difference in MIC value between the VIM-7 wt, VIM-7 D120A and VIM-7 H224Y (Table 5). 
This is most likely due to the fact that VIM-7 was cloned into the pDEST14 expression vector, 
which is tightly regulated for leaky expression, and the genes to not be expressed without the 
presence of IPTG (Table 1). 
 












































































E. coli VIM-7 wt 12 2 0.19 2 0.032 1.5 0.38 0.064 0.023
E. coli VIM-7 D120A 8 2 0.125 2 0.032 0.75 0.38 0.047 0.023
E. coli VIM-7 H224Y 8 2 0.125 3 0.023 0.75 0.38 0.064 0.023
 
Activity testing by using nitrocefin 
In order to examine the difference in activity between the VIM-7 wt and the VIM-7 
D120A and H224Y mutants, an enzyme assay with the substrate nitrocefin was performed. 
By using the spectrophotometer SpectraMax and the software SoftMax and the extinction 
coefficient of the substrate, the substrate concentration of the stock solutions were determined. 
The nitrocefin was diluted in buffer E (Table 1). The proteins were diluted in buffer F with 
BSA (Table 1). The measurements were initiated by measuring 50 µl of buffer E together 
with 40 µl nitrocefin substrate. 10 µl of protein with a concentration of 0.1 µM was added to 
the solution, and the absorbance at specific wavelengths (Table 3) was measured at 25ºC for 
20 min. The substrate nitrocefin was measured in a 96 well flat bottom non-binding surface 





Figure 28: Activity measurements with nitrocefin. Nitrocefin was used as substrate for comparing the activity 
of VIM-7wt (o), VIM-7 H224Y mutant (Δ) and VIM-7 D120A mutant (□). All of the proteins had a 
concentration of 0.1 µM.  
 
The VIM-7 H224Y mutant appeared to have an activity that was slightly lower than 
VIM-7 wt with the substrate nitrocefin (Figure 28). The VIM-7 D120A mutant, on the other 
hand, turned out to have very low activity (Figure 28).  
This measurement was also performed with different antibiotics (results shown in the 
appendix). The results from these enzyme activity tests were used to find what concentration 
of the enzymes to use and to compare the activity of the VIM-7 wt, the VIM-7 D120A mutant 





To study the enzyme activity and the reaction rates of the recombinantly produced 
proteins VIM-7 wt, VIM-7 D120A mutant and VIM-7 H224Y mutant, enzyme kinetic studies 
were performed. Six different antibiotics; ertapenem, meropenem, cefoxitin, cefepime, 
ceftazidime and cefuroxime, were used as substrates and dissolved in buffer E (Table 1). The 
substrate solutions for kinetic analyses were made as dilutions in the range of 2-1000 µM. The 
kinetic analysis was performed in two parallels to obtain reliable results. The TEV-cleaved 
and affinity purified proteins were diluted in buffer F (Table 1) to final concentrations of 10 
µM or 50 µM. The measurements were performed using 96 well falcon UV microplates, 
because of the substrates’ ability to interact with the plastic in 96 well non-binding 
microplates, which was used for activity assays with the substrate nitrocefin (Figure 28).  
VIM-7 wt and VIM-7 H224Y mutant were able to hydrolyse all of the antibiotics 
tested (Figure 28). The concentration of VIM-7 D120A mutant was increased to a final 
concentration of 100 nM, which was ten times higher than the concentration of  the VIM-7 wt 
and the VIM-7 H224Y, without the substrate ertapenem to be fully hydrolysed (Figure 29b, 
below). Thus, taken together with the activity measurement with nitrocefin (Figure 28), VIM-
7 D120A mutant was considered inactive. Due to this conclusion, enzyme kinetic analysis of 




Figure 29: Enzyme kinetics VIM-7 wt (■), VIM-7 D120A (only in b) and VIM-7 H224Y (▲) with different 
substrates. a) Ertapenem using 10 nM VIM-7wt and 10 nM VIM-7 H224Y mutant, b) Ertapenem using 100 nM 
VIM-7 D120A mutant, c) Meropenem using 10 nM VIM-7 wt and 10 nM VIM-7 H224Y mutant, d) Cefuroxime 
using 10 nM VIM-7 wt and 10 nM VIM-7 H224Y mutant, e) Cefepime using 50 nM VIM-7 wt and 10 nM VIM-
7 H224Y mutant, f) Cefoxitin using 50 nM VIM-7 wt and 10 nM VIM-7 H224Y mutant, g) Ceftazidime using 




 First, assay trials with all enzymes were performed to get an indication of which 
enzyme concentration to use for complete hydrolysis of the substrates (Appendix). 
 
The catalytic efficiency, kcat/Km (Table 4) of VIM-7 H224Y mutant was higher for 
four of six substrates when comparing with the VIM-7 wt. The substrates meropenem and 
cefuroxime had a higher catalytic efficiency with VIM-7 wt in comparison with VIM-7 
H224Y mutant, with two times higher for meropenem and 1.5 times higher catalytic 
efficiency for cefuroxime.  The fours substrates with higher catalytic efficiency with the VIM-
7 H224Y mutant than the VIM-7 wt were ertapenem with four times higher, cefepime with 
ten times higher, cefoxitin with six times higher, and ceftazidime with five times higher 
catalytic efficiency.  
The values for kcat, the turnover number which indicates the reaction velocity of the 
hydrolysis, were higher for VIM-7 H224Y, compared to VIM-7 wt for all substrates.  
Km, gives an indication of how strong the substrates are bound to the active site. The 
lower the value of Km, the more firm is the binding of substrate to enzyme. In our assay, Km 
values are higher for VIM-7 wt with three of six substrates. The three substrates with higher 
Km for VIM-7 wt are meropenem and cefuroxime, both with significant difference to the Km 
of VIM-7 H224Y, while the substrate cefepime was not significantly higher when considering 









































































































































































































































































































































































































































































The proteins VIM-7 wt, VIM-7 D120A and VIM-7 H224Y mutants were all expressed 
and purified, but because of the low protein concentration of VIM-7 D120A mutant, 
crystallization trials were performed for the VIM-7 H224Y mutant due to high amount of 
protein available. 
In order to obtain a crystal structure of the VIM-7 H224Y mutant, crystallization trials, 
both by hand and by a robot, were set up. In both of these trials, the TEV-cleaved and affinity 
purified VIM-7 H224Y was used, thus, not gel filtered. One crystal was obtained with the 
robot, under the conditions of 25% PEG 3350, 0.1 M BisTris pH 5.5 and 0.2 M NaCl (Figure 
30), was sent with researcher Hanna-Kirsti Schrøder Leiros (NorStruct, UiT) to the 
synchrotron at Max-LAB Lund, Sweden, for X-ray data collection. 
 
 
Figure 30: A crystal of VIM-7 H224Y. The enzyme was grown by using the KSCG screen, and used for X-ray 
data collection. The condition for the crystallization was 25% PEG 3350, 0.1M BisTris pH 5.5 and 0.2 M NaCl. 
 
The crystal (Figure 30) was cryoprotected in 32% polyethylene glycol 5000 
monomethyl ether (PEG 5K MME), 5% glycerol and 0.1 M succinate buffer pH 7.0, and then 
flash frozen in liquid nitrogen (performed by researcher Hanna-Kirsti Schrøder Leiros, 





Figure 31: Diffraction image of VIM-7 H224Y mutant. The first image in the VIM-7 H224Y data set, 
collected with wavelength of 1.0000 Å, a crystal to detector distance of 135.47 mm and on a detector with height 
of 225 mm giving 1.45 Å resolution at the edge and 1.2 Å resolution in the corners of the detector. 
 
The diffraction image of the VIM-7 H224Y mutant is shown in figure 31. The 
structure of VIM-7 H224Y mutant was solved by molecular replacement using VIM-7 wt as 
search model (PDB ID: 2Y87) [29]. The resolution, which is a measure of the resolvability in 
the electron density map of a molecule, was 1.40 Å in the final dataset. The space group P43 
indicates that the crystal belongs to the tetragonal crystal class, which is the same as for VIM-
7 wt. The unit cell parameters (Table 6) are very similar to the parameters from the VIM-7 wt 
[29] despite the different crystallization condition. The data collection at Max-LAB in Lund, 
Sweden, was done with a wavelength of 1.000 Å. I represent the measured intensity values of 
reflections, while σI represents the estimated standard deviation in the measurement of the 
intensity values. This means that <I>/<σI> gives the average degree to which measured 
reflection intensities stand out over background. The unique reflections, <I>/<σI> (Table 6), 
were approximately nine times greater than the background noise around the reflection. Rsym 
is a measurement of the agreement between the multiple recordings for a given unique 
reflection. It is a value of the degree to which each reflection deviates from the average of all 
of its multiply measured counterparts. A value of 6.6% is low, and indicates that the data are 
in good agreement with each other.  
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The model for VIM-7 H224Y mutant was refined to a low R value (11.78%, Table 6), 
which describes how well the model agrees with the experimental X-ray diffraction data [129]. 
The Rfree value which is computed by a small set of intensities chosen randomly [134], had a 
value of 15.64%, which also is low. To describe the confidence of the model, a B-factor is 
introduced. High values of B-factor imply uncertainty in atom positions. The refinement 
showed a reasonable mean B-value (18.4 Å2).  
 
Table 6: Data collection from X-ray crystallization and crystallographic refinement statistics of VIM-7 

























a     Rsym =Σj|I(h)j-<I(h)>|/ΣjI(h)j, where I(h)j is the scaled observed intensity of the jth observation of reflection h, 
and <I(h)> is the mean value of corresponding symmetry-related reflection. 
b  Rfree = Σh||Fobs|-|Fcalc||/(Σh|Fobs|), where|Fobs| and |Fcalc| are the observed and calculated structure factor 
amplitudes for all reflections (R-factor) and the reflections applied in the test Rfree set. 
Data collection   
X-ray source LUND I911-3 
Space group P43 
Unit cell (Å)  a=b=70.23, c=47.03 
Resolution (Å) 30-1.40 (1.48-1.40) 
Wavelength (Å) 1.0000 
No. unique reflections 43 649 (5 673) 
Multiplicity 3.5 (2.0) 
Completeness (%) 96.6 (86.8) 
Mean (<I> /<I>) 9.1 (3.1) 
Rsym (%)
a 6.6 (16.5) 
Refinement  
Resolution (Å) 25-1.40 
R-factor (all reflections) (%) 11.78 
R-free (%)b 15.64 
Average B-factor (Å2)  
 All atoms 18.4 
 Protein  16.4 
 Water molecules  31.8  





Figure 32: Electron density maps. a) The starting and b) final election density maps of residue 224 in the VIM-
7 H224Y crystal structure. The 2Fo-Fc map is displayed at 1.5  (blue) and the Fo-Fc maps at +3.5 σ (green) and -
3.5 (red). The atoms are colour-coded on the basis of atom type (cyan, carbon; blue, nitrogen; red, oxygen; 
yellow, sulfur; and orange, zinc). 
 
 The crystal structure of the VIM-7 H224Y mutant was solved with molecular 
replacement of VIM-7 wt (Figure 32). The Fourier difference map Fo-Fc is the difference map, 
where the green electron density represents the presence of electrons which are not provided 
by the structure of VIM-7 wt. The red electron density in the Fo-Fc represents the presence of 
excessive electrons, which is present when a histidine five-carbon-ring is substituting a 
tyrosine six-carbon-ring (Figure 32a). The blue electron density map is given by the 2Fo-Fc, 
which is given by the Fo observed structure factors and Fc calculated structure factor (Figure 
32b).  
The cysteine 221 residue in VIM-7 wt (Figure 32a) was oxidized in the VIM-7 H224Y 
mutant (Figure 32b), which is a result of not sufficient amounts of β-mercaptoethanol in the 
protein solution prior to crystallization [29].  
 To conclude, the VIM-7 H224Y mutant was crystallized, and the structure of the 






Cloning of VIM-7 wt and site-directed mutagenesis of VIM-7 D120A, VIM-
7 D120N and VIM-7 H224Y 
The blaVIM-7 wild type gene, coding for the protein sequence A26-E264, was 
successfully cloned into the expression vector pDEST14 with an N-terminal his-tag and a 
TEV cleavage site, using the Gateway cloning system. 
Mutations were introduced into blaVIM-7, and the three different pDEST14 constructs 
encoding the VIM-7 mutations D120A, D120N and H224Y (Figure 18) were Sanger 
sequenced to analyse whether the desired point mutations were present (Figure 19). All 
mutants were successfully obtained. 
 
Challenges with protein expression 
The VIM-7 wt, VIM-7 D120A and VIM-7 H224Y mutants were all expressed in small 
scale in the E. coli strains Rosetta2(DE3)pLysS and BL21(DE3)star/pRARE/pLysS. The 
VIM-7 wt, VIM-7 D120A and VIM-7 H224Y mutants were produced in large scale 
expression in Rosetta2(DE3)pLysS successfully, and was purified and further used for 
enzyme kinetic studies and crystallization trials for the VIM-7 H224Y mutant.  
The introduction of VIM-7 D120N mutant, on the other hand, was not observable in 
either small or large scale protein expression. The sequencing result of VIM-7 D120N mutant 
gave a low-intensity chromatogram (figure 19), which might indicate that the sequencing 
reaction was not optimal. However, even if the intensity was low, the spectre did show correct 
mutation nucleotide and the sequence was overall correct. In several attempts, in solubility 
experiments with different buffers, and in small and large scale expression experiments, the 
VIM-7 D120N mutant would not be induced. The reason for this is not known.  
An alternative experiment to detect the recombinant VIM-7 D120N mutant would be 
to analyse the mutant by western blotting. In this method, proteins are initially separated by 
gel electrophoresis before the protein are transferred to a nitrocellulose membrane, where they 
are detected by using epitop specific antibodies [135]. This method would be much more 
sensitive than SimpleBlue Safe standard stained SDS-PAGE.  
Screening for new clones of VIM-7 D120N mutant might, however, be a more 





Structure and enzymatic activity hypothesis for the VIM-7 D120N mutant 
The VIM-7 D120N mutant was expected to be isostructural to the VIM-7 wt structure, 
because the atoms of the amino acid asparagine (N) fill the same space as the amino acid 
aspartic acid (D). The aspartic acid amino acid has a negative charge, whereas asparagine 
amino acid has a polar uncharged side chain, which, according to previous studies of D120N 
mutations [4], would have a great impact on the activity of the mutant.  
The metal-binding of D120 in metallo-β-lactamases play an important role in catalysis. 
The position of D120, with a negatively charged oxygen located directly below the bridging 
group in the active site, shows how it coordinates Zn2 2+ (Figure 6). Previous studies have 
shown that D120 plays an important role in the enzymatic activity. It has also been 
hypothesized that D120, in addition to being a metal-binding ligand, electrostatically interacts 
with the bridging hydroxide, properly positioning it for nucleophilic attack on the substrate 
(Figure 6) [4, 45, 136].  
Previous studies of the D120N mutant in the L1 metallo-β-lactamase (L1) from 
Stenotrophomonas maltophilia have shown that the mutant conserves the dinuclear Zn center 
with a bridging water molecule present. The L1 D120N mutant is catalytically hindered, as 
the coordination of Zn2 is changed. The water molecule was also not coordinated by the L1 
D120N mutant. The catalytic activity of the L1 D120N mutant was lower than the activity of 
the L1 wt, due to the loss of substrate-enzyme interaction and the loss of proton transfer to the 
substrate amide nitrogen [4, 45]. 
The effect of the D120N mutation in VIM-7, however, remains to be shown. 
 
Purification of VIM-7 wt, VIM-7 D120A mutant and VIM-7 H224Y mutant 
The proteins VIM-7 wt, VIM-7 D120A mutant and VIM-7 H224Y mutant were all 
successfully purified by the affinity purification method both before (Figures 21, 23 and 25) 
and after TEV-cleavage and dialysis (Figures 22, 24 and 26).  
The SDS-PAGE analysis of the VIM-7 H224Y mutant was overloaded with protein. 
Hence, other proteins on the gel were more visible (Figure 26b). Size-exclusion purification, 
by gel filtration, was performed on the VIM-7 H224Y mutant (Figure 27). The observed 
shoulder in the gel filtration chromatogram (Figure 27) of the VIM-7 H224Y mutant indicates 
that the protein solution might contain multimeric complexes.  
A pink colour of fractions 23 and 24 (Figure 25a) of the VIM-7 H224Y mutant after 
the first affinity purification appeared. This might be due to the presence of the two Zn ions in 
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the VIM-7 H224Y. Another assumption was a contamination, however, is less likely. The 
colour of the fractions had nothing to do with the high absorbance in the purification (Figure 
25a), as the pink colour is measured at approximately 700 nm, and not 280 nm that was used 
in the purification. The SDS-PAGE analysis, however, showed extensive yields of the VIM-7 
H224Y protein with contaminants. This was further supported by measuring the protein 
concentration of the pooled fractions, 7.7 mg/ml. 
 
Epsilometer test  
 The results from the E-tests (Table 5) were not in accordance with the enzyme kinetic 
studies (Table 4). One reason for this might be that the expression vector, pDEST14, which is 
tightly regulated. The E. coli strain Rosetta2(DE3)pLysS has a pLysS plasmid with a T7 
lysozyme site, which inactivated the T7 RNA polymerase, making it unable to bind to the T7 
promoter of the pDEST14 vector, hence, not expressing the VIM-7 gene. The low degree of 
expression did not affect the antibiotics, which was tested. For E-tests performed in medicine, 
the pDEST14 vector is not used as expression vector. Had the genes been cloned into another 
vector with constitutive expression, or IPTG added to the genes, we would expect the result of 
the VIM-7, VIM-7 D120A and VIM-7 H224Y to be different. 
 
Activity testing by using nitrocefin 
The E-test did not show the difference in activity of the VIM-7 wt and the VIM-7 
D120A mutant and the VIM-7 H224Y mutant, while the difference in activity was shown by 
testing with the substrate nitrocefin (Figure 28). The VIM-7 H224Y mutant had an activity 
which was similar, and slightly lower than VIM-7 wt, for the substrate nitrocefin. The 
nitrcefin assay showed that the VIM-7 D120A mutant was inactive compared to the VIM-7 wt 
and the VIM-7 H224Y mutant.  
 
Comments on the enzyme kinetics experimental design of the enzyme 
kinetics assay 
For the enzyme kinetic studies, duplicates of all reactions with fourteen different 
substrate concentrations, ranging from 0.2 µM to 1000 µM, were performed. The addition of 
enzymes was required to be done as simultaneously as possible, since the hydrolysis of the 
substrates starts immediately. For the adding of enzyme to substrate one was depended on a 
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multi-channel pipette. By having a 96-well plate and a pipette with eight functional pipette 
tips, the application of the enzyme was done in four operations manually with a few seconds 
between the applications. Hence, the values in the hydrolysis would be somewhat different, 
than values from an assay where the addition of enzymes was done simultaneously, for 
example by a robot that could handle the whole plate simultaneously. Fewer outliers would 
probably be defined. 
The enzyme kinetics studies of VIM-7 wt and VIM-7 H224Y mutant were 
successfully performed with the antibiotics; ertapenem, meropenem, cefuroxime, cefepime, 
ceftazidime and cefoxitin. The VIM-7 D120A mutant was only tested with the substrate 
ertapenem. The VIM-7 D120A enzyme, even at a final concentration ten times higher than the 
VIM-7 wt and VIM-7 H224Y mutant, did still not hydrolyse the substrate. Taken together 
with the activity testing with nitrocefin (Figure 28), we concluded that the VIM-7 D120A 
mutant was inactive.  
 
Enzyme kinetics and structure hypothesis for the VIM-7 D120A mutant 
The VIM-7 D120A mutant was only tested with the carbapenem substrate, ertapenem. 
The reason for not screening the whole panel of substrates was its inactivity toward nitrocefin. 
By increasing the concentration of the VIM-7 D120A ten times, compared to the 
concentration of the VIM-7 wt and the VIM-7 H224, the substrate would still not be 
hydrolysed completely (Figure 29b). The Km value of the VIM-7 D120A is relatively high, 
compared to all of the Km values of the VIM-7 wt and the VIM-7 H224Y mutant, and the 
kcat/Km has a significantly low value. With such low rate efficiency, the enzyme-substrate 
complex converts a lesser proportion of the substrate to product. Thus, we concluded that the 
VIM-7 D120A mutant was inactive, and other substrates needed not to be tested for kinetic 
studies. The low activity of the VIM-7 D120A mutant was in accordance with previous 
studies of how alanine substitution of the D120 residue causes a decrease in catalytic 
efficiency in the metallo-β-lactamase IMP-1 [136]. As previously described, it is known that 
the D120 residue in metallo-β-lactamase is important for catalysis [4, 45].  
As no crystallization trials for the VIM-7 D120A mutant were set up, due to a lack of 
protein, the structure is yet unknown. However, mutation of the D120 residue to alanine in 
metallo-β-lactamase IMP-1 did not show any modification in the overall protein fold [136]. 
By assuming that the overall fold of the VIM-7 D120A mutant is identical to the VIM-7 wild 
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type except for the substituted residue, one can predict that the activity of the mutant will be 
similar to previously described D120A mutations of metallo-β-lactamases.  
In the predicted in silico structure of VIM-7 D120A mutant, the D120 residue is 
expected to be replaced by an alanine residue, while the other residues in the protein remain at 
the same position (Figure 33). The alanine at position 120, being hydrophobic and at a larger 
distance from Zn than aspartic acid, will most likely not bind and activate the metal-bridging 
water/hydroxide between the two Zn ions. The D120 residue does activate and bind to the Zn 
and the metal-bridging water/hydroxide via hydrogen bonding from its carboxylate side chain 
(Figure 6). The optimal position of the Zn ions for catalytic activity, which are coordinated by 
the D120 residue in the wild type, is most likely not facilitated by the D120A mutant. The loss 
of interaction with Zn is likely to result in a more flexible active site than in the VIM-7 wt, 
which further prevents productive substrate-binding. The D120A residue might also alter the 
process of proton transfer from water to nitrogen of the substrate. One of the Zn ions in the 
metallo-β-lactamase VIM-7 D120A might even be lost in a similar way to what was shown 




Figure 33: (a) The active site of VIM-7 wt PDB ID: 2Y87 [29], and (b) how the active site of the 
mutated VIM-7 D120A is predicted to be. The green indicate carbon atoms, red indicate oxygen, blue indicate 
nitrogen, yellow indicate sulphur, dark grey indicate Zn ions, light grey between the two Zn ions indicate the 
metal-bridging with water, and grey atoms indicate the target residue for mutation in a) and the mutation in b). 




Enzyme kinetics of the VIM-7 wt and the VIM-7 H224Y mutant 
The enzyme kinetic assay results showed to have a higher catalytic efficiency for four 
of six substrates for the VIM-7 H224Y mutant compared to the VIM-7 wt (Table 4). The two 
β-lactam substrates, the carbapenem meropenem and the cephalosporin cefuroxime a higher 
catalytic efficiency was shown for the VIM-7 wt over the H224Y mutant.  
The Km values of the carbepenem substrate ertapenem (structure shown in Figure 34a) 
with the VIM-7 wt and the VIM-7 H224Y mutant is similar when considering the standard 
deviations (Table 4). The kcat is four times higher for the VIM-7 H224Y mutant than for the 
VIM-7 wt. The catalytic efficiency is four times higher for the VIM-7 H224Y mutant, 
compared to the VIM-7 wt. The decisive factor for the higher catalytic efficiency for the 
VIM-7 H224Y mutant is the velocity of the reaction. 
The Km values of the VIM-7 wt and the VIM-7 H224Y mutant with the carbapenem 
substrate meropenem (structure shown in Figure 34b) shows a Km value which is two times 
higher for the VIM-7 H224Y mutant, indicating that the substrate binds more firmly to the 
VIM-7 wt (Table 4). The turnover number kcat of VIM-7 wt and the VIM-7 H224Y mutant are 
similar. The catalytic efficiency, kcat/Km, is two times greater for VIM-7 wt compared to the 
VIM-7 H224Y mutant, which implies that the increased binding of the meropenem substrate 






Figure 34: Structure formula of β-lactam substrates, the carbapenems a) ertapenem, b) meropenem and 
the cephalosporins c) cefuroxime, d) cefepime, e) cefoxitin and f) ceftazidime. The side groups R1 and R2 
are indicated by red lines. The structure formulas were obtained from Wikipedia. 
  
The enzyme kinetics with the cephalosporin substrate cefuroxime with a polar R2 
group (structure shown in Figure 34c) showed a higher catalytic efficiency with VIM-7 wt 
compared to the VIM-7 H224Y mutant. The kcat of VIM-7 wt was lower, by being 
approximately 70% of the kcat of VIM-7 H224Y. The Km of VIM-7 H224Y mutant is two 
times higher than the Km of VIM-7 wt. Although the enzymatic reaction is faster for VIM-7 




For the cephalosporin substrate cefoxitin with a polar R2 group (shown in Figure 34e), 
the binding affinity, Km, of the VIM-7 wt and the VIM-7 H224Y mutant is similar. The 
turnover number, kcat, is six times higher for the VIM-7 H224Y mutant than for the VIM-7 wt. 
The decisive factor for the catalytic efficiency, kcat/Km, for cefoxitin with the VIM-7 wt and 
the VIM-7 H224Y mutant is the kcat, as the catalytic efficiency for the VIM-7 H224Y mutant 
is six times higher, than for cefoxitin with the VIM-7 wt. 
 
Enzyme kinetics of the VIM-7 wt compared to the VIM-7 H224Y mutant with 
positively charged substrates 
The cephalosporin substrate cefepime has a positively charged R2 group (Figure 34d). 
The catalytic efficiency was found to be ten times higher for the VIM-7 H224Y mutant, 
compared to the VIM-7 wt. The binding affinity, Km, of the VIM-7 wt and the VIM-7 H224Y 
mutant is similar when considering the standard deviations. The turnover number, kcat, is ten 
times higher for the VIM-7 H224Y mutant than for the VIM-7 wt. Hence, the decisive factor 
of the catalytic efficiency is the turnover number. The VIM-7 wt has a histidine residue which 
carries a positive charge when protonated, while the VIM-7 H224Y mutant, with a tyrosine in 
this position, has a neutral side chain. Two positive charges in the VIM-7 wt and cefepime 
may cause repulsion, and the binding of positively charged substrate to the positively charged 
active site may not be as firm as the binding of the substrate to a neutral active site. Hence, the 
cephalosporin substrate cefepime will bind more efficiently to the VIM-7 H224Y mutant.  
The cephalosporin substrate ceftazidime was computationally docked into the VIM-7 
H224Y structure. From the results in table 4, the VIM-7 H224Y mutant showed a five times 
higher catalytic efficiency kcat/Km than the VIM-7 wt. For ceftazidime the Km of VIM-7 
H224Y mutant is two times lower than the Km for VIM-7 wt, which means that the substrate 
binds better to the VIM-7 H224Y mutant. The kcat of VIM-7 H224Y mutant is three times 
higher than the wild type, which means that the reaction for the mutant is three times faster. 
The structure of the substrate ceftazidime (Figure 34f) has, like the substrate cefepime, a 
positively charged R2 group, the VIM-7 wt has a histidine residue which carries a positive 
charge when protonated, while the VIM-7 H224Y mutant has a neutral side chain. The active 
site of the VIM-7 H224Y mutant is less positively charged than the active site of the VIM-7 
wt, and the positively charged substrate ceftazidime encounters less repulsion in the active 
site of the VIM-7 H224Y mutant. The ceftazidime might also form hydrogen bonding with 
the water molecule which is bound to the tyrosine 224 residue (TYR224 in Figure 35). This 
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strong bonding between the water and the tyrosine residue is not present in the wild type. 
Hence, the substrate ceftazidime will bind more efficiently to the H224Y mutant.  
 To sum up, the catalytic efficiencies of the cephalosporin substrates carrying a 
positively charged R2 group seem to be higher for the VIM-7 H224Y mutant than the 
catalytic efficiency for the VIM-7 wt.  
 
Figure 35: The cephalosporin substrate ceftazidime computationally docked in the VIM-7 H224Y mutant. 
The docking was performed using the structure of the VIM-7 which has been docked with ceftazidime, 
superimposed on the solved crystal structure of the VIM-7 H224Y mutant. green indicate the secondary structure 
of the VIM-7 H224Y mutant, the cyan indicate the carbon atoms in the active site residues, the blue indicate the 
nitrogen atoms, the red indicate the oxygen atoms, yellow indicate the sulphur atoms. The red spheres indicate 
water molecules, while orange spheres indicate Zn ions. The magenta indicates the carbons in the cephalosporin 
substrate ceftazidime. The positively charged R2 group (Figure 35f) is in the left of the ceftazidime substrate. 




The VIM-7 H224Y structure 
The overall structure of the VIM-7 H224Y mutant had a αββα fold, as the solved 
crystal structure of VIM-7 [29].  
The obtained VIM-7 H224Y crystal structure, although not located close enough to 
directly form bonding with the Zn ions, shows to influence the catalytic efficiency. One 
observation made was that the Arginine residue at position 228 in the VIM-7 H224Y mutant 
had changed the conformation when comparing to the previously solved VIM-7 structure. The 
tyrosine at position 224 makes two hydrogen bonds; one hydrogen binds to an A231, and 
another hydrogen binds to a water molecule, which again, hydrogen binds to His196, which is 
one of the Zn coordinating residues (Figure 32). The two hydrogen bonds formed in the VIM-
7 H224Y mutant make the active site of the protein more rigid compared to the active site in 
the wild type. This may result in reduced flexibility for the other residues in the active site, 




















The VIM-7 wild type gene, coding for the protein sequence A26-E264, with an N-
terminal hexahis-tag and a TEV cleavage site was cloned. The VIM-7 mutations D120A, 
D120N and H224Y were designed, produced and sequenced. The VIM-7 wt, the VIM-7 
D120A mutant and the VIM-7 H224Y mutant were produced, affinity purified and activity 
tested with the nitrocefin assay. In addition, the VIM-7 H224Y mutant was purified with gel 
filtration. Enzyme kinetic studies were performed on the VIM-7 wt and the VIM-7 H224Y 
mutant. The VIM-7 D120A mutant was tested against the substrate ertapenem, and showed to 
be inactive. The crystal structure of the VIM-7 H224Y mutant was solved, and the overall 
structure fold was maintained compared to the native VIM-7. The  
The mutation of D120 residue to an alanine amino acid results in an inactive enzyme, 
which strengthen the hypothesis of the importance of the D120 residue in the active site. The 
mutation of H224 residue to a tyrosine amino acid results in a significantly higher catalytic 
efficiency when comparing to the VIM-7 wt. For substrates like the carbapenem substrate 
ertapenem, the cephalosporin substrates cefepime, the ceftazidime and the cefoxitin the 
mutant showed four, ten, five and six times higher catalytic activity respectively.  
In this study, it was shown that the mutation of one single amino acid had a huge 
impact on the catalytic properties of the enzyme, as shown with the VIM-7 D120A mutant 















 There were not set crystallization trials for the VIM-7 D120A mutant, and this would 
be the next natural step in studying the structure of the VIM-7 D120A mutant in detail. For 
the VIM-7 D120N mutant, new clones would be screened in order to obtain the recombinant 
protein. The VIM-7 D120N mutant would further contribute in the studies of the importance 
of the D120 residue in the active site of the VIM-7. Further, the VIM-7 D120A mutant, the 
VIM-7 D120N mutant and the VIM-7 H224Y mutant should be docked with different 
antibiotic substrates in order to study their interaction. The inactive VIM-7 D120A mutant is 
more likely to obtain an enzyme-substrate crystal structure, compared to active mutants, as the 
substrate in the inactive D120A mutant probably will be remained intact and not 
enzymatically cleaved. 
 The next step is to screen for inhibitors and perform cocrystallization of the inhibitor-
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Figure 50: Enzyme kinetics for comparing the activity of VIM-7wt, VIM-7 D120A and VIM-7 H224Y. The 
protein concentration of all the proteins was 0.1 µM. The measurement was done by starting with 990 µl of 
buffer A together with 10 µl substrate. 2 µl of the protein with a final concentration of 0.1 µM was added to the 
solution, and the concentration was measured for 20 min. 
a) Ertapenem, b) Meropenem, c) Cefuroxime, d) Ceftazidime, e) Cefepime and f) Cefoxitin. 
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